Protocol I8F- MC-GPGH (c) 
 
A Randomized, Phase 3, Open- Label Trial Comparing the  Effect of LY3298176 versus Titrated 
Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes  (SURPASS -3) 
 
[STUDY_ID_REMOVED] 
 
Approval Date: 30-Jul-2020 
I 8 F -M C -G P G H( c) Cli ni c al Pr ot o c ol P a g e 1
L Y 3 2 9 8 1 7 6 Pr ot o c ol I 8 F -M C -G P G H ( c) 
A R a n d o mi z e d, P h a s e 3, O p e n - L a b el Tri al C o m p ari n g t h e 
Eff e ct of L Y 3 2 9 8 1 7 6 v er s u s Titr at e d I n s uli n D e gl u d e c o n 
Gl y c e mi c C o ntr ol i n P ati e nt s wit h T y p e 2 Di a b et e s 
( S U R P A S S - 3) 
2 0 1 8 -0 0 3 4 2 2 -8 4 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
L Y 3 2 9 8 1 7 6 ,u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y 
a n d C o m p a n y or it s s u b si di ari e s .
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e. I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e c t t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
L Y 3 2 9 8 1 7 6 
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Pr ot o c ol El e ct r o ni c all y Si g n e d a n d A p pr o v e d b y Lill y: 2 6 O C T 2 0 1 8 
A m e n d m e nt ( a ) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 0 6 -M ar c h -2 0 1 9 
A m e n d m e nt ( b) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y :  1 5 -A pr -2 0 2 0 
A m e n d m e nt ( c) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n a p pr o v al d at e pr o vi d e d 
b el o w. 
A p pr o v al D at e: 3 0- J ul- 2 0 2 0 G M T 
I8F-MC-GPGH(c) Clinical Protocol Page 2
LY3298176Table of Contents
Section Page
Protocol  I8F-MC-GPGH(c) A Rando mized, Phase 3, Open -Label Trial 
Com paring the Effect of LY3298176 versus Titrated Insulin 
Degl udec on Glycemic Control in Pat ients with Type 2 Di abetes 
(SURPASS -3)..................................................................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 9
2. Schedule of Activities....................................................................................................... 14
3. Introduction ...................................................................................................................... 22
3.1. Study  Rati onale ............................................................................................................ 22
3.2. Background .................................................................................................................. 23
3.3. Benefit/Risk Assessment .............................................................................................. 24
4. O bject ives and Endpo ints.................................................................................................. 25
5. Study  Design ..................................................................................................................... 27
5.1. Overall Design ............................................................................................................. 27
5.2. Number of Parti cipants .................................................................................................32
5.3. End of Study  Definit ion............................................................................................... 32
5.4. Scientific Rationale for Study  Design ........................................................................... 32
5.5. Justification for Dose ................................................................................................... 33
6. Study  Popul ation............................................................................................................... 34
6.1. Inclusio n Cri teria.......................................................................................................... 34
6.2. Exclu sion Criteria........................................................................................................ 35
6.3. Lifest yle Restrict ions.................................................................................................... 38
6.4. Screen Failures ............................................................................................................. 38
7. Treatments ........................................................................................................................ 39
7.1. Treatments Administered ............................................................................................. 39
7.1.1. Packaging and Labeling ....................................................................................... 40
7.1.2. Medical Devices ................................................................................................... 40
7.2. Method of Treatment Assignment ................................................................................ 40
7.2.1. Selection and Timing o f Doses ............................................................................. 40
7.2.1.1. LY3298176 .................................................................................................... 40
7.2.1.2. Insulin Degludec ............................................................................................. 41
7.3. Blinding ....................................................................................................................... 42
7.4. Dosage Modifica tion.................................................................................................... 42
7.4.1. Study  Drugs ......................................................................................................... 42
I8F-MC-GPGH(c) Clinical Protocol Page 3
LY32981767.4.2. Reduction and/or Discont inuat ion of Conco mitant 
Antihyperglycemic Medicat ions........................................................................... 42
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 43
7.6. Treatment Compliance .................................................................................................43
7.7. Concomitant Therapy ................................................................................................... 44
7.7.1. Management of Patients with Gastrointestinal Symptoms ..................................... 45
7.8. Treatment after the End of the Study ............................................................................ 46
7.8.1. Treatment after Study  Com pletion........................................................................ 46
7.8.2. Speci al Treatm ent Consi derat ions........................................................................ 46
8. Discontinuati on Cri teria .................................................................................................... 47
8.1. Discontinuati on from Study  Treatm ent......................................................................... 47
8.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 47
8.1.2. Temporary  Discont inuat ion from Study  Treatm ent............................................... 48
8.1.3. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 48
8.2. Discontinuati on from the Study .................................................................................... 49
8.3. Lost to Follow -up......................................................................................................... 49
9. Study  Assessments and Procedures ................................................................................... 51
9.1. Efficacy Assessments ................................................................................................... 51
9.1.1. Primary Efficacy  Assessments and Procedures ..................................................... 51
9.1.2. Secondary  Efficacy  Assessments and Procedures ................................................. 51
9.1.3. Exploratory  Efficacy  Assessments and Procedures ............................................... 51
9.1.4. Appropriateness of Assessments .......................................................................... 52
9.2. Adverse Events ............................................................................................................ 52
9.2.1. Serious Adverse Events ........................................................................................ 53
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 54
9.2.2. Adverse Events of Special Interest ....................................................................... 54
9.2.2.1. Hypoglycemia ................................................................................................ 54
9.2.2.2. Severe, Persistent Hy perglycemia ................................................................... 55
9.2.2.3. Pancreat itis..................................................................................................... 56
9.2.2.4. Thyroid Malignancies and C -Cell Hyperplasia ................................................ 57
9.2.2.5. Major Adverse Cardio vascular Events ............................................................ 58
9.2.2.6. Supraventricular Arrhyt hmias and Cardiac Conduction 
Disorders ........................................................................................................ 58
9.2.2.7. Hypersensi tivity Events .................................................................................. 58
9.2.2.7.1. Inject ion Site Reacti ons ............................................................................ 58
9.2.2.7.2. Anti-Drug Ant ibodies ............................................................................... 58
9.2.2.8. Diabetic Ret inopathy  Com plicat ions............................................................... 59
9.2.2.9. Hepatobiliary  Disorders .................................................................................. 59
I8F-MC-GPGH(c) Clinical Protocol Page 4
LY32981769.2.2.10. Severe Gastrointestinal Adverse Events .......................................................... 59
9.2.2.11. Acute Renal Events ........................................................................................ 59
9.2.2.12. Metabo lic Acidosis, Including Diabetic Ketoacidosis ..................................... 59
9.2.2.13. Amputati on/Peri pheral Revascularizat ion....................................................... 59
9.2.2.14. Major Depressive Disorder/Suicidal Ideat ion.................................................. 60
9.2.3. Com plaint Handling ............................................................................................. 60
9.3. Treatment of Overdose .................................................................................................60
9.4. Safety........................................................................................................................... 60
9.4.1. Electrocardiograms .............................................................................................. 60
9.4.2. Vital Signs ........................................................................................................... 60
9.4.3. Laborat ory Tests .................................................................................................. 61
9.4.4. Immunogenicit y Assessments .............................................................................. 61
9.4.5. Safety Moni toring ................................................................................................ 62
9.4.5.1. Hepati c Safet y Moni toring .............................................................................. 62
9.5. Pharmacokinet ics......................................................................................................... 62
9.6. Pharmacodynamics ...................................................................................................... 62
9.7. Pharmac ogeno mics ...................................................................................................... 62
9.7.1. Who le Blood Samples for Pharmacogenet ic Research .......................................... 62
9.8. Biomarkers ................................................................................................................... 63
9.9. Heal th Econom ics........................................................................................................ 63
9.9.1. Diabetes Treatm ent Satisfaction Questionnaire ..................................................... 64
9.9.2. Impact of Weight on Self- Percept ion Quest ionnaire ............................................. 64
9.9.3. Abilit y to Perform  Physical Act ivities of Daily Living ......................................... 64
9.9.4. European Qualit y of Life ...................................................................................... 64
10. Statistical Considerations .................................................................................................. 66
10.1. Sample Si ze Determinat ion.......................................................................................... 66
10.2. Popul ations for Analyses .............................................................................................. 66
10.3. Statistical Analyses ...................................................................................................... 67
10.3.1 .General Statist ical Considerat ions........................................................................ 67
10.3.2. Treatment Group Comparabilit y........................................................................... 68
10.3.2.1. Patient Disposi tion.......................................................................................... 68
10.3.2.2. Patient Characteri stics................................
.................................................... 68
10.3.2.3. Concomitant Therapy ..................................................................................... 68
10.3.2.4. Treatment Compliance .................................................................................... 68
10.3.3. Efficacy Analyses ................................ ................................................................ 68
10.3.3.1. Primary Analyses ........................................................................................... 68
10.3.3.2. Secondary  Analyses ........................................................................................ 69
10.3.3.3. Terti ary/Exploratory  Analyses ........................................................................ 70
I8F-MC-GPGH(c) Clinical Protocol Page 5
LY329817610.3.4. Safety Analyses .................................................................................................... 70
10.3.4.1. Hypoglycemic Events ..................................................................................... 70
10.3.4.2. Gastrointestinal Events ................................................................................... 70
10.3.4.3. Adjudicated Cardiovascular Events ................................................................ 71
10.3.4.4. Central  Laboratory  Measures, Vi tal Signs, and 
Electrocardiograms ......................................................................................... 71
10.3.5. Evaluat ion of Immunogenicit y............................................................................. 71
10.3.6. Other Analyses ..................................................................................................... 71
10.3.6.1. Health Economics ........................................................................................... 71
10.3.6.2. Subgroup Analyses ................................ ......................................................... 71
10.3.7. Interim Analyses .................................................................................................. 72
11. References ........................................................................................................................ 73
12. Appendices ....................................................................................................................... 76
I8F-MC-GPGH(c) Clinical Protocol Page 6
LY3298176List of Tables
Table Page
Table GPGH.1. Schedule of Act ivities.................................................................................... 15
Table GPGH.2. Object ives and Endpo ints............................................................................... 25
Table GPGH.3. Study  Treatm ents........................................................................................... 39
Table GPGH.4. Titration of  Insulin Degludec ......................................................................... 41
Table GPGH.5. Criteria for Use of Concomitant Medicat ions that May Interfere wit h 
Efficacy and Safet y Assessments in Study  GPGH .......................................... 45
Table GPGH.6. Descript ion of Analysis Sets .......................................................................... 66
I8F-MC-GPGH(c) Clinical Protocol Page 7
LY3298176List of Figures
Figure Page
Figure GPGH.1. Illustrati on of  study  design for Clinical Protocol I8F -MC-GPGH. .................. 28
I8F-MC-GPGH(c) Clinical Protocol Page 8
LY3298176List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 77
Appendix 2. Clinical Laboratory  Tests ............................................................................... 82
Appendix 3. Study  Governance Considerat ions.................................................................. 84
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 88
Appendix 5. World Heal th Organizat ion Classifica tion of  Diabetes and Di agnosti c 
Criteria ................................
.......................................................................... 89
Appendix 6. Classificat ion of Contraceptive Methods ........................................................ 90
Appendix 7. Changes to Study  Procedures due to the COVID -19 Pandemic ...................... 91
Appendix 8. Protocol  Amendment I8F -MC-GPGH(c)
A Rando mized, Phase 3, Open -Label Tri al Com paring the Effect of 
LY3298176 versus Titrated Insulin Degludec on Glyc emic Control  in 
Patients wi th Type 2 Di abetes (SURPASS -3)................................................ 92
I 8 F -M C -G P G H( c) Cli ni c al Pr ot o c ol P a g e 9
L Y 3 2 9 8 1 7 6 1. S y n o p si s 
Title of St u d y: 
A Ra n d o mize d, P hase 3, O pe n -La bel Tri al  C o m pari n g t he Effect of L Y 3 2 9 8 1 7 6 vers us Ti trate d 
I ns uli n De gl u dec o n Gl yce mic C o ntr ol i n P ati e nts wi t h  T y pe 2 Di a betes ( S U R P A S S - 3) 
R ati o n ale: 
T y pe 2 di a betes m elli t us ( T 2 D M) is a m eta b o lic c o n dit i o n c haracterize d b y i m paire d gl yce mic 
c o ntr ol  ca use d b y  i ncrease d i ns uli n resista nce a n d pr o gressi ve beta -cell fail ure a n d c o nse q ue nt l y 
i na de q uate i ns uli n secret i o n. As t he disease pr o gresses, treat me nt wit h m ult i ple dr u g s will be 
nee de d t o ac hie ve gl yce mic c o ntr o l ( A merica n Dia betes Ass ociat i o n [A D A ] 2 0 1 7). W he n oral 
a nt i h y per gl yce mic me dicat i o ns ( O A M s) are i ns ufficie nt t o reac h tar get gl yce mia, i njecta ble 
t h era pi es are a d de d (I nz ucc hi et al . 2 0 1 5).  Basal i ns uli ns, s uc h as de gl u dec , are c o m m o nl y  use d 
as t h efirst i njecta ble af t er f ail ure of oral  t hera p y .A de q uatel y t it rate d i ns uli n de gl u dec t hera p y , 
i n c o m bi nat i o n wi t h  O A Ms , ma y ac hie ve t he tar get gl yce mic le vel; h o we ver, t h e t w o m ai n 
li mitati o ns of i ns uli n treat me nt are wei g ht gai n a n d h y p o gl yce mia ( Zi n ma n et al . 2 0 1 2, Pa n et al . 
2 0 1 6). 
I njecta ble i ncreti n - base d treat me nts (f or e xa m ple ,G L P -1 [ gl uca g o n -li ke pe pt i de -1] rece pt or 
a g o nists) are als o c o m m o nl y use d i n c o m bi nat i o n wi t h  O A Ms t o ac hie ve a n d mai ntai n gl uc ose 
c o ntr ol ( A D A 2 0 1 7, I nz ucc hi et al . 2 0 1 5). W hile ass ociate d wit h l o wer ris k f or h y p o gl yce mia 
a n d eit her wei g ht ne utral o r wei g ht l oss effects, c urre nt pre parati o ns are di recte d at a si n gle 
m o lec ular tar get ( G L P - 1 rece pt ors) a n d pr o vi de d ose -de pe n de nt gl uc ose -l o weri n g effects ,w hic h 
ca n be li mite d b y gastr oi ntest i nal t olera bilit y ( Na uc k 2 0 1 6). 
L Y 3 2 9 8 1 7 6 is a 3 9 -a mi n o aci d s y nt het ic pe pti de wit h a g o nist acti vit y at b ot h t he GI P 
( gl uc ose -de pe n de nt i ns uli n otr o pic p ol y pe pt i de) a n d G L P -1 rece pt ors. Its str uct ure is base d o n 
t h e GI P se q ue nce a n d i ncl u des a C 2 0 fatt y  di -aci d m oi et y t h at 
 It i s a d mi nistere d o nce -wee kl y  ( Q W) b y s u bc uta ne o us ( S C) i nject i o n. 
St u d y  I 8 F -M C -G P G H ( G P G H) is a P hase 3, m ult ice nter, ra n d o mize d, o pe n -la bel, parallel -gr o u p 
st u d y  t hat will i n vest i gate t he effects of treat me nt wit h L Y 3 2 9 8 1 7 6, 5 m g, 1 0 m g, a n d 1 5 m g 
Q W, c o m pare d wi t h  ti trate d i ns uli n de gl u dec i n patie nts wit h T 2 D M nai ve of  i ns uli n treat m e nt 
w h o ha ve i na de q uate gl yce mic c o ntr ol o n sta ble d oses of metf or mi n wit h or wi t h o ut a 
s o di u m -gl uc ose c o -tra ns p orter - 2 i n hi bit or ( S G L T -2i ). C CI 
I8F-MC-GPGH(c) Clinical Protocol Page 10
LY3298176Objective(s)/Endpoints:
Objectives Endpoints
Primary
To demonstrate that QW LY3298176 10 mg 
and/o r 15 mg is noninferior to insulin 
degludec for change from baseline in HbA1c 
at 52 weeksMean change in HbA1c 
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate that QW LY3298176 5 mg is 
noninferio r toinsulin degludec for change in 
baseline in HbA1c at 52 weeks
To demonstrate that QW LY3298176 5 mg, 
10 mg, and/or 15 mg is superior to insulin 
degludec for change from baseline in weight 
at 52 weeks Mean change in HbA1c 
Mean cha nge in body weight 
To demonstrate that QW LY3298176 5 mg, 
10 mg, and/or 15 mg is superior to insulin 
degludec for change from baseline in HbA1c 
at 52 weeks Mean change in HbA1c 
To demonstrate QW LY3298176 5 mg, 10 
mg, and /or 15 mg is superior to insulin 
degludec for the proportion of patients with
HbA1c target value of <7.0 %(53 mmol/mol) 
at 52 weeksHbA1c
Additional Secondary (not controlled for type 1
error)
To demonstrate that QW LY3298176 5 mg, 
10 mg, and /or15mg is superior to insulin 
degludec at 52 weeks
To compare LY3298176 5 mg, 10 mg, and 
15mg to insulin degludec at 52 weeks for:Mean change in fasting serum glucose
(central lab) from baseline
Proportio n of patients achieving an HbA1c 
target values of ≤6.5% (48 mmol/mol) and
<5.7% (39 mmol/mol)
Mean change in 7 -point self -monitored blood 
glucose (SMBG) profiles from baseline
Proportio n of pat ients who achieved weight
loss≥5%,≥10%, and ≥15% from baseline
Patient- reported outcomes:
oDiabetes Treatment Satisfaction 
Questionnaire status/ Diabetes
Treatment Satisfaction Questionnaire 
change 
oImpact of Weight on Self -Perception
oAbility to Perform Physical 
I8F-MC-GPGH(c) Clinical Protocol Page 11
LY3298176Objectives Endpoints
Activities of Da ily Living
Safety
To compare LY3298176 5 mg, 10 mg, and 
15mg to insulin degludec for:Treatment -emergent adverse events (TEAEs)
Early  discontinuation of study drug due to 
adverse events (AEs)
Adjudicated pancreatic AEs
Serum calcitonin
Incidence of allergic and hypersensitivity 
reactions 
Incidence of treatment -emergent anti -drug 
antibodies to LY3298176
Mean change in systolic and diastolic blood 
pressure and heart rate from baseline 
Occurrence ofhypoglycemic episodes
Incidence of initiation of rescue therapy for 
severe ,persistent hyperglycemia
Abbreviations :  HbA1c =hemoglobin A1c; HDL=high density lipoprotein; QW =once weekly; T2DM = type 2 
diabetes mellitus; TG =triglycerides; VLDL =very low density lipoprotein
Summary of Study Design:   
Study  GPGH i s a Phase 3, mult icenter, randomized, open -label, parallel -arm study  that will  
investigate the effects of treatment with LY3298176 5 m
g, 10 m g, and 15 m g QW compared 
with titrated insulin degludec in patients with T2DM who have inadequate glycemic control on 
stable doses of metformin wit h or wi thout an SGLT -2i.
Treatment Groups and Duration:   
Study  GPGH will consist of 3 periods:  an approximately 3 -week screening/lead -inperiod, 
followed by a 52- week treatm ent peri od,and a 4 -week safet y follow -up peri od.  Patients will be 
rando mized in a 1:1:1:1 ratio to receive LY3298176 doses :  5 mg QW, 10 m g QW, 15 m g QW, 
or insulin degludec once daily (QD).  Pati ents will  be stratified at randomizat ion based on 
HbA1c ( ≤8.5%, >8.5% [69 mmo l/mol]), country , and use of concomitant oral ant idiabet ic 
treatm ents (m etformin alo ne, m etformin plus an SGLT -2i).
Number of Patients :
A total o f approximately  1420 pat ients will be randomiz ed in a 1:1:1:1 rati o to receive 
LY3298176 doses:  5 m g QW (355 patients), 10 mg QW (355 patients), 15 mg QW (355 
patients), orinsulin degludec QD (355 patients).
Statistical Analysis:
Efficacy Analyses :
I8F-MC-GPGH(c) Clinical Protocol Page 12
LY3298176Efficacy and safet y will be assessed using the modified intent ion-to-treat (m ITT) popul ation, 
which consists of all rando mly assigned participants who are exposed to at least 1 dose of study 
drug.  There will be 2 estimands of interest in comparing efficacy of LY3298176 doses wi th 
insulin degludec relat ive to the primary endpo intof mean change in HbA1c from baseline to the 
52-week visit . The “efficacy” est imand represents efficacy prior to discontinuat ion of study  drug 
without confounding effects of rescue therapy  for persistent severe hyperglycemia.  The 
“treatm ent-regimen” est imand represents the efficacy irrespect ive of adherence to invest igational 
product or introduction of rescue therapy  for persi stent severe hyperglycemia.
For the FDA, the primary  efficacy  assessm ent will  be guided by the “treatment -regimen” 
estimand.  This assessment will analyze change from baseline in HbA1c to the 52-week visit 
using an analysis o f covari ance (ANCOVA )with term s:  treatm ent, country , 
baseline 
concomitant oral ant idiabet ic treatm ent (m etformin alo ne, metformin plus SGLT -2i), and 
baseline HbA1c as a covariate .  The ANCOVA analysis will be conducted using Full Analysis 
Set at 52 -week visit, which consists of all available changes from baseline in HbA1c data at the 
52-week visit, irr espect ive of whether they were obtained while the participants had discontinued 
the study  drug or whether the participant had been given rescue medicat ion.  Addit ionally, data 
for subjects with missing change fro m baseline in HbA1c values will be imputed b ased on 
observed data in the same treatment group from subjects who had their efficacy measure at the 
Week 52 visit assessed after early discont inuat ion of study drug and/or init iation of rescue 
medicat ion (retri eved dropouts).  If there are not sufficient numbers of retrieved dropouts, 
baseline data may be used to develop an imputation model.   Analysis will be conducted with 
multiple imputations, and statistical inference over mult iple imputations will be guided by  the 
method proposed by  Rubin (1987).
For all other purposes, the primary efficacy assessment will be guided by the “efficacy” 
estimand.  This assessment will use efficacy analysis set which consists of data obtained before 
the init iation of any  rescue therapy  and before premature treatment discon tinuation.  The analysis 
model for change from  baseline in HbA1c assessed over time will be a mixed model for repeated 
measures (MMRM), with terms:  treatment, visit, and treatment -by-visit interaction, country , 
baseline conco mitant oral  antidiabet ic treat ment (met formin alo ne, m etformin plus SGLT -2i) as 
fixed effects, and baseline HbA1c as a covariate.  An unstructured covariance structure will 
model relati onshi p of within-patient errors.  
A 0.3% boundary  will be used for noninferiorit y evaluat ions betwee n LY3298176 and insulin 
degludec relat ive to mean change in HbA1c fro m baseline.
Sincethe estimands are different , each of the 2 primary  efficacy assessments will be conducted 
at a family-wise ty pe 1 error rate of 0.05.  Addi tional details, including analysis methods for key
secondary  endpoints and a strategy  for controlling overall family -wise type 1 error rate at a n
alpha of 0.05 of primary  and key  secondary  endpoint evaluat ion, will be provided in the 
statist ical analysis plan (SAP).
I8F-MC-GPGH(c) Clinical Protocol Page 13
LY3298176Safety Analysis:
Unless specified otherwise, s afety assessment swill be based on all available data, irrespect ive of 
whether they  were obtained while the participants had discont inued the study  drug or whether the 
participant had been given rescue medicat ion.Summary stat istics will be provided for incidence 
of TEAEs, serious AEs, and study  discontinuati on due to AEs or death from the time of first 
dose through end of safet y follow-up.  Counts and proportions of subjects experiencing AEs will 
be reported for each treatment group, and Fisher’s exact test will be used to compare the 
treatm ent groups.  For continuous laboratory  analytes, summary  stati stics will be provided by 
visit, with statist ical co mpar isons amo ng treatment at each visit conducted using an MMRM 
analysis.  S elected safet y analys es maybe conducted excluding data after the introduc tion of
another anti-hyperglycemic therapy  (for example, rescue therapy ).Addit ional details, including 
analysis of AEs of special interest, will be provided in the S tatistical Analysis Plan (SAP) .
I8F-MC-GPGH(c) Clinical Protocol Page 14
LY32981762.Schedule of A ctivities
The Schedule o f Activities described below should be fo llowed for all pat ients enrolled in 
Study GPGH.  However, for those patients whose participat ion in this study  isaffected by  severe 
acute respiratory  syndrom e coronavi rus 2 ( SARS -CoV -2), the virus that causes the novel 
Coronavirus Disease 2019 (COVID -19), please refer to Appendix 7 for addi tional instructi ons
.
I8F-MC-GPGH(c) Clinical Protocol Page 15
LY3298176Table GPGH. 1. Schedule of A ctivities
Study Period I Study Period 
IIStudy Period III
Screening Lead 
inTreatment Period Safety F/U
Visit 1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21ET
b801
Week of Treatment -3 -2 0 1 2 3 4 5 6 7 8 10 12 14 16 20 24 32 40 46 524 weeks Post 
End of Tx
Allowable Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7
Fasting VisitdX X X X X X X X X X X X
Telephone Visit X X X X X X
Informed consent X
Randomization X
Clinical Assessments
Medical historyeX
Physical X X X X
Height X
WeightfX X X X X X X X X X X X X
Waist circumference X X X X X X X X X X X X
Electrocardiogram X X X X X
Vital signs (2 sitting 
BP and HR)gX X X X X X X X X X X X X X X X
Dilated Fund oscopic 
Exam inationhX
Adverse events X X X X X X X X X X X X X X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X X X X X X X
Review hypoglycemic 
events collected in 
diaryX X X X X X X X X X X X X X X X X X X X X
I8F-MC-GPGH(c) Clinical Protocol Page 16
LY3298176Study Period I Study Period 
IIStudy Period III
Screening Lead 
inTreatment Period Safety F/U
Visit 1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ETb801
Week of Treatment -3 -2 0 1 2 3 4 5 6 7 8 10 12 14 16 20 24 32 40 46 524 weeks Post 
End of Tx
Allowable Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7
Fasting VisitdX X X X X X X X X X X X
Telephone Visit X X X X X X
Patient Education
Diabetes educationi,jX
BG meter, SMBG 
trainingjX
Dispense BG 
meter/supplies, as 
neededX X X X X X X X X X X X X X X
Study drug injection 
trainingjX
Hand out diary, 
instruct in usejX X X X X
Remind patients 
about 7 -point SMBGkX X X X
Review 7 -point 
SMBG values 
collected in diaryX X X X
Dispense study drug X X X X X X X X X
Observe patient 
administer 
LY3298176lX
Patient returns study 
drugs and injection X X X X X X X X X X X X X
I8F-MC-GPGH(c) Clinical Protocol Page 17
LY3298176supplies
Study Period I Study Period 
IIStudy Period III
Screening Lead 
inTreatment Period
Safety F/U
Visit 1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ETb801
Week of Treatment -3 -2 0 1 2 3 4 5 6 7 8 10 12 14 16 20 24 32 40 46 524 weeks Post 
End of Tx
Allowable Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7
Fasting VisitdX X X X X X X X X X X X
Telephone Visit X X X X X X
Assess study drug 
complianceX X X X X X X X X X X X X X X X X X X
Review insulin dose 
and adjustment per 
TTT algorithmmX X X X X X X X X X X X X X X X X X X
Assess compliance 
with insulin dose 
adjustment TTT 
algorithmnX X X X X X X X X X X X X
I8F-MC-GPGH(c) Clinical Protocol Page 18
LY3298176Study Period 
IStudy Period IIStudy Period 
III
Screening 
Lead inTreatment Period Safety F/U
Visit 1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ETb801
Week of Treatment -3 -2 0 1 2 3 4 5 6 7 8 10 12 14 16 20 24 32 40 46 524 weeks Post 
End of Tx
Allowable Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7
Fasting VisitdX X X X X X X X X X X X
Telephone Visit X X X X X X
Laboratory Tests
Serum pregnancy testoX
Urine pregnancy testpX X X X X
Follicle -stimulating 
hormone testqX
Chemistry panel XrX X X X X X
Fasting serum glucose X X X X X X X X X X X X
Lipid panel X X X X X
Urinary albumin/
creatinine ratioXrX X X X
Serum creatinine, eGFR 
(CKD -EPI)sXrX X X X X
Calcitonin XrX X X X X X
Hematology XrX X X X X X
HbA1c X X X X X X X X X X X X
Pancreatic amylase, 
lipaseXrX X X X X X
ImmunogenicitytX X X X X X X X
PK sample for 
ImmunogenicityuX X X X X X X X
Anti-GAD antibody
X
Stored samples
I8F-MC-GPGH(c) Clinical Protocol Page 19
LY3298176Study Period 
IStudy Period IIStudy Period 
III
Screening 
Lead inTreatment Period Safety F/U
Visit 1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ETb801
Week of Treatment -3 -2 0 1 2 3 4 5 6 7 8 10 12 14 16 20 24 32 40 46 524 weeks Post 
End of Tx
Allowable Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7
Fasting VisitdX X X X X X X X X X X X
Telephone Visit X X X X X X
Pharmacogenetic stored 
sampleX
Nonpharmacogenetic 
stored sample s:
EDTA plasma ,Serum ,
P800 plasma -2.0mlX X X X X X
Patient Reported Outcomesv
APPADL X X X
EQ-5D-5L X X X
IW-SP X X X
DTSQs X
DTSQc X X
Abbreviations:  ADA =anti-drug antibodies; APPADL =Ability to Perform Physical Activities of Daily Living ; BG =blood glucose; BP =blood pressure; 
CKD -EPI =Chronic Kidney Disease -Epidemiology; DTSQc =Diabetes Treatment Satisfaction Questionnaire change; DTSQs =Diabetes Treatment 
Satisfaction Questionnaire status; ECG =electrocardiogram; eCRF =electronic case report form ; EDTA =ethylenediaminetetraacetic acid ; eGFR =estimated 
glomerular filtration rate; EQ-5D-5L = European Quality of Life -dimensio ns;ET=early termination; F/U =follow -up; GAD =glutamic acid decarboxylase; 
HbA1c =hemoglobin A1c; HR =heart rate; IW-SP=Impact of Weight on Self -Perception; PK =pharmacokinetics; PRO =patient -reported outcome;
SGLT -2 = sodium -glucose co -transporter -2; SMBG =self-monitored blood glucose; TTT =treat to target; Tx =treatment.
I8F-MC-GPGH(c) Clinical Protocol Page 20
LY3298176aBaseline assessments must be completed before processing in the interactive web -response sy stem.
bPatients who are unable or unwilling to continue in the study for any reason will perform an ET visit.  If the patient is dis continuing during an unscheduled 
visit, that visit should be performed as the ET visit.  If the patient is disco ntinuing during a scheduled visit, that visit should be performed as an ET visit.  
Visit 801 ( safety  follow -up v isit) should be performed 4 weeks after the ET visit as the final study visit.
cThe visit date is determined in relation to the date of the ran domization visit (± the allowed visit window).
dOn visits 3, 5, 7, 11, 13, 15, 16, 17, 19, 21, ET, and at follow -up, patients should be reminded to report to the site in a fasting condition, after a period of 
approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin and SGLT -2i(if 
used).
eMedical history includes assessment of preexisting conditions (including history of gallbladder disease, cardiovascular disea se,diabe tic retinopathy ,and 
medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco) .
fWeight mea surements must be in kilograms.
gVital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where 
required.  The participant should sit quietly for 5 minutes before vital sign measurements are taken .  For each parameter, 2 measurements will be taken using 
the same arm; the recordings should be taken at le ast 1 minute apart .  BP must be taken with an automated blood pressure machine .
hDilated fund oscopic examination will be performed by a neye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to 
exclude patients with proliferative diabetic retinopathy and/or diabetic maculopathy or nonproliferative diabetic retinopathy that requires acute treatment .  The 
results from this examination will be recorded on a specific retinopathy eCRF as a baseline me asure of retinopathy.  Follow up dilated fundoscopic
examination should be performed w hen clinically indicated, and, the results recorded on the retinopathy eCRF.
iIncludes counseling on diet and exercise, symptoms and management of hypoglycemia, etc.
jAll training should be repeated as needed to ensure patient compliance. 
kPatient is required to collect two 7 -point SMBGs on nonconsecutive days prior to the next visit.  A 7 -point SMBG consists of measurements before and 2 
hours after each of 3 main meal s within the same day and at bedtime.  These SMBG profiles will be collected by the patient within 2 weeks prior to the 
assigned visits.  If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used.  If more than two ( 2)
7-point SMBG profiles are available, the 2 most recent profiles on nonconsecutive days should be used.
lPatients should administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization.
mDuring the first 8 weeks, the dose adjustment will be determined by the investigator in discussion with the patient by follow ing a TTT algorithm.  After 
Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit.  Patients will 
have weekly visits (clinic or phone) in the first 8 weeks and then biweekly visits (clinic or phone) until Week 16 in order t o improve compliance with the TTT 
algorithm.
nAssessment of the patient’s compliance to the TTT algorithm will be collected in the eCRF at Visits 7, 9, 11, 13 , 15and 21 for the period since the previous 
clinic visit.
oA serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.
pA urine pregn ancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of 
childbearing potential only.  Additional pregnancy tests will be performed at Visits 13, 17, 19 and 21. Pregnancy tes ts may alsobe performed at the 
investigator’s discretion during the study.  If required per local regulations and/or institutional guidelines, pregnancy tes ting can also occur at other times 
dur
ing the study treatment period.
I8F-MC-GPGH(c) Clinical Protocol Page 21
LY3298176qFollicle -stimulating hormon e test performed at Visit 1 for postmenopausal women at least 45years of age with an intact uterus, not on hormone therapy, and 
who have had spontaneous amenorrhea for more than 6 months and less than 12 months and estradiol levels consistent with a postm enopausal state (FSH ≥40 
mIU/mL and estradiol <30 pg/mL).
rScreening visit assessment will serve as baseline.
sThe CKD -EPI equation will be used by the central lab to estimate and report eGFR. 
tIn the event of systemic drug hypersensitivity reactions ( immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and an 
exploratory immune safety sample.
uPK samples for immunogenicity must be taken prior to drug administration.
vAll PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition or completed after the patient 
has sufficiently recovered from the preceding visit procedures.
Note: Patients will be encouraged to collect a daily fasting BG and a weekly 4 -point SMBG .  Missing a fasting BG measurement will not be considered 
a protocol deviation.
I 8 F -M C -G P G H( c) Cli ni c al Pr ot o c ol P a g e 2 2 
L Y 3 2 9 8 1 7 6 3. I ntr o d u cti o n 
3. 1. St u d y R ati o n al e 
T y pe 2 di a betes m elli t us ( T 2 D M) is a m eta b o lic c o n dit i o n c haracterize d b y i m paire d gl yce mic 
c o ntr ol  ca use d b y  i ncrease d i ns uli n resista nce a n d pr o gressi ve beta -cell fail ure a n d c o nse q ue nt l y 
i na de q uate i ns uli n secret i o n. T y pe 2 di a betes mellit us is ass ocia te d wi t h  c o m or bi di ti es s uc h as 
i ncrease d wei g ht or o besit y,  h y perte nsi o n, i ncrease d bl o o d li p o pr otei n c o nce ntrati o ns, a n d a 
hi g her ri s k f or macr o -a n d micr o vasc ular c o m plicati o ns.  T o pre ve nt t hese c o m plicati o ns, ti g ht 
gl yce mic c o ntr ol is rec o m me n de d ( A mer ica n Dia betes Ass ociat i o n( A D A) 2 0 1 7). 
T he treat me nt f or T 2 D M us uall y starts wit h lifest yle a n d diet c ha n ges f o ll o we d b y ste p wise 
a d di ti o n of  or al  a nt i h y per gl yce mic me dicati o ns ( O A M s) t o m ai ntai n a de q uate gl uc ose c o ntr ol 
(I nz ucc hi et al . 2 0 1 5 ).  Wit h f urt h er pr o gressi o n of t he di sease , O A M will be i ns ufficie nt t o reac h 
a n d mai ntai n t he t hera p y  g o al  of  tar get gl yce mia, a n d ma n y  pat ie nt s will e ve nt uall y  r e q ui r e 
i njecta ble t hera pies. Cli nical g ui deli nes ( A D A 2 0 1 7, I nz ucc hi et al .2 0 1 5) c urre ntl y  rec o m me n d 
i ni ti at i n g basal i ns uli n i n pat ie nt s wi t h  T 2 D M ei t h er di rect l y af t er m et f o r m i n or after ma xi mizi n g 
a c o m bi nat i o n of or al  a nti dia betic dr u gs ( O A Ds ), wi t h  or wi t h o ut gl uca g o n -li ke pe pti de - 1 
( G L P -1) rece pt or a g o nists. A de q uatel y t it rate d de gl u dec t hera p y , i n c o m bi nat i o n wi t h  or al  
treat m e nt, f re q ue nt l y ac hie ves t he tar get gl yce mic le vel alt h o u g h it is fre q ue nt l y ass ociate d wit h 
w ei g ht i ncrease a n d e ve nt ual h y p o gl yce mia ( Zi n ma n et al . 2 0 1 2 , Pa n et al. 2 0 1 6 ). 
I njecta ble i ncreti n -base d treat me nts (f or e xa m ple ,G L P -1 rece pt or a g o nists) are als o c o m m o nl y 
use d i n c o m bi nati o n wit h O A Ms t o ac hie ve a n d mai ntai n gl uc ose c o ntr ol ( A D A 2 0 1 7, I nz ucc hi 
2 0 1 5).  W hile ass ociate d wit h l o wer ris k f or h y p o gl yce mia a n d eit her wei g ht ne utral or wei g ht 
l o ss effects, c urre nt pre parati o n s are di recte d at a si n gle m o le c ular tar get ( G L P -1 rece pt ors) a n d 
pr o vi de d ose -de pe n de nt gl uc ose -l o weri n g effects ,w hic h ca n be li mite d b y gastr oi ntesti nal ( GI) 
t ol era bilit y ( Na uc k 2 0 1 6). 
T he m eta b o lic effects of G L P -1 rece pt or a g o nists ca n be e n ha nce d b y c o m bi ni n g t he m wit h t he 
acti o ns of  ot her e nter o pa ncreat ic h or m o nes. Gl uc ose -de pe n de nt i ns uli n otr o pic p ol y pe pti de 
( GI P) sti m ulates i ns uli n secret i o n i n a gl uc ose -de pe n de nt m a n ner, a n d m a y e xert s o m e ot her 
acti o ns be y o n d i ts r ol e as a n i ncreti n t hat c o ul d p ote nt ia ll y  i m pr o ve t hera pe utic efficac y i n 
c o m bi nat i o n wi t h  G L P -1 rece pt or a g o ni sts al o ne ( f or e xa m ple ,i m pr o ve d li pi d h o me o stasi s a n d 
w h o le b o d y  e ner g y  m eta b o lis m) ( Na uc k a n d Meier 2 0 1 8, As mar et al . 2 0 1 6). 
L Y 3 2 9 8 1 7 6 is a 3 9 -a mi n o aci d s y nt het ic pe pti de w it h a g o nist acti vit y at b ot h t he GI P a n d G L P - 1 
rece pt ors. Its str uct ure is base d o n t he GI P se q ue nce a n d i ncl u des a C 2 0 fatt y  di -aci d m oi et y  t hat 
It i s a d mi nistere d as o nce -wee kl y  ( Q W) s u bc uta ne o us ( S C) 
i nject i o n( C os k u n et al . 2 0 1 8). 
St u d y  I 8 F -M C -G P G H ( G P G H) is a P hase 3, m ult ice nter, ra n d o mize d, o pe n -la bel, parallel -gr o u p 
st u d y  t hat will i n vest i gate t he effects of treat me nt wit h L Y 3 2 9 8 1 7 6 5 m g, 1 0 m g, a n d 1 5 m g 
Q W, c o m pare d wi t h  ti trate d i ns uli n de gl u dec i n pati e nts wi t h  T 2 D M na ive of i ns uli n treat me nt 
w h o ha ve i na de q uate gl yce mic c o ntr ol o n sta ble d oses of metf or mi n wit h or wi t h o ut a 
s o di u m -gl uc ose c o -tra ns p orter -2 i n hi bit or ( S G L T - 2i). C CI 
I8F-MC-GPG H(c) Clinical Protocol Page 23
LY32981763.2. Background
Three LY3298176 clinical studi es have com pleted dosing and analysis:  a Phase 1 study , 
Study I8F-MC-GPGA (GPGA), and two Phase 2 studies, Study I8F -MC-GPGB (GPGB) and 
I8F-MC-GPGF (GPGF).  
Phase 1 Study  GPGA was a combinat ion of single ascending dose (SAD) and mult iple ascending 
dose stu dy in healthy subjects and a m ultiple dose study  in pat ients with T2DM.  Study GPGA 
investigated safety , tolerabili ty, pharmacokinet ics (PK), and pharmacodynamics (PD) of 
LY3298176 administered as SC inject ions.  A total of 142 subjects (89 healthy subjects and 
53patients wi th T2DM) received at least 1 dose of treatment.  Doses of LY3298176 ranged from  
0.25 m g to 8 mg in the SAD ( with maximum  tolerated dose ach ieved at 5 m g); m ultiple doses 
from 0.5mg to 4.5 mg QW; and titrated doses up to 10 mg QW for 4 weeks in healthy subjects; 
and mult iples doses at 0.5 mg and 5 mg QW and t itrated to 15 mg QW for 4 weeks in patients 
with T2DM.  
The safet y,tolerabilit y,and PK/PD profiles of LY3298176 at doses and escalat ion regimens 
administered in this Phase 1 study  supported further development of LY3298176 for QW dosing 
in patients with T2DM.
A 26 -week Phase 2 stud y (GPGB) assessed the efficacy, tolerabilit y, and safet y of 4 doses 
(1mg/5 mg/10 mg and 15 mg) of LY3298176 versus pl acebo and an active comparator 
(dulagluti de 1.5 m g) in318patients wi th T2DM wit h inadequate glycemic control on diet and 
exercise alone or on a stable do se of m etformin monotherapy .The doses of 10 mgand 15 mg 
were attained by t itration (Frias et al. 2018) .Additio nally,a 12 week, placebo -controlled study
(GPGF )assessed the efficacy  and 
3different titration schemes to attain doses as high as 15 mg in 
T2DM pati ents. 
Study  GPGB dem onstrated that LY3298176 5-mg, 10 -mg, and 15 -mg doses significant ly 
lowered hem oglobin A1c (HbA1c) and body  weight in a dose -dependent manner in patients wit h 
T2DM in co mpar ison to placebo .In addit ion, reducti ons in HbA1c in the LY3298176 5-, 10-, 
and 15 -mgdoses were greater than wit h dul aglut ide 1.5 m g QW .  
Similar to the GLP -1 receptor
agonist class and the Phase 1 Study ,most of the LY3298176 adverse events ( AEs)were 
GI-related, consist ing mainly o fnausea, vo miting, and diarrhea and were dose -dependent. The 
GI AEs were usually mild to moderate in intensit y. Serious AEs (SAEs) were balanced across 
the treatment groups and none of the groups in eithe r study  reported severe hypoglycemia (Frias
et al. 2018) .
As it was recognized that the titration scheme emplo yed i n Study  GPGB was unlikely to be 
optimal for the reducti on of  GI-related AEs expected with LY3298176 , Study  GPGF was 
designed to explore alternat ive titration schemes (longer time interva ls between dose escalations 
anddifferent dose escalations) to support evaluat ion of optimize d dosing regimen(s) in Phase 3.
Thesedata suppo rt continued development of LY3298176 as a therapy  for T2DM.  
I8F-MC-GPG H(c) Clinical Protocol Page 24
LY32981763.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated AEs of LY3298176 are to be found in the Invest igator’s Brochure (IB).
In addition, detailed informat ion about the known and expected benefits and risks of insulin 
degludec may be found in the insulin degludec package insert ( Tresiba USPI, 2015 [WWW] ).
I8F-MC-GPG H(c) Clinical Protocol Page 25
LY32981764.Objectives and Endpoints
Table GPGH. 2shows the object ives and endpoints of the study .
Table GPGH. 2. Objectives and Endpoints
Objectives Endpoints
Primary
To demonstrate that QW LY3298176 10 mg 
and/or 15 mg are noninferior to insulin 
degludec for change from baseline in HbA1c 
at 52 weeks Mean change in HbA1c 
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate that QW LY3298176 5 mg is 
noninferio r toinsulin degludec for change in 
baselin ein HbA1c at 52 weeks
To demonstrate that QW LY3298176 5 mg, 
10 mg, and/or 15 mg is superior to insulin 
degludec for change from baseline in weight 
at 52 weeks 
To demonstrate that QW LY3298176 5 mg, 
10mg, and/or 15 mg is superior t o insulin 
degludec for change from baseline in HbA1c 
at 52 weeks Mean change in HbA1c 
Mean cha nge in body weight 
Mean change in HbA1c 
To demonstrate QW LY3298176 5 mg, 10 
mg, and/or 15 mg is superior to insulin 
degludec for the proportion of patients with
HbA1c target value of <7.0 %(53 mmol/mol) 
at 52 weeksHbA1c 
Additional Secondary (not controlled for type 1 
error)
To demonstrate that QW LY3298176 5 mg, 
10 mg, and /or15mg is superior to insulin 
degludec at 52 weeks for:Mean change in fasting serum glucose (central 
lab) from baseline
Proportio n of patients achieving an HbA1c 
target value of ≤6.5% (48 mmol/mol) ,<5.7% 
(39 mmol/mol)
Mean change in 7 -point self -monitored blood 
glucose (SMBG) profiles from baseline
Proportio n of pat ients who achieved weight 
loss≥5%, ≥10%, and ≥15% from baseline
To compare LY3298176 5 mg, 10 mg, and 
15mg to insulin degludec at 52 weeks for:Patient- reported outcomes:
oDiabetes Treatment Satisfaction 
Questionnaire status/ Diabetes
Treatment Satisfaction Questionnaire 
change 
oImpact of Weight on Self -Perception
oAbility to Perform Physical 
I8F-MC-GPG H(c) Clinical Protocol Page 26
LY3298176Objectives Endpoints
Activities of Daily Living
Safety
To compare the safety of LY3298176 5 mg, 
10 mg, and 15 mg to insulin degludec for:Treatment -emergent adverse events (TEAEs)
Early  discontinuation of study drug due to 
adverse events (AEs)
Adjudicated pancreatic AEs
Serum calcitonin
Incidence of allergic and hypersensitivity 
reactions
Incidence of treatment -emergent anti -drug 
antibodies to LY3298176
Mean change in systolic and diastolic blood 
pressure and heart rate from baseline 
Occurrence of hypoglycemic episodes
Incidence of initiation of rescue therapy for 
severe persistent hypergl ycemia
Tertiar y/Exploratory
To compare LY3298176 5 mg, 10 mg, and 15 
mgwith insulin degludec with respect for the 
followin g:Change in lipids (total cholesterol, HDL, 
VLDL, and TG)
Changes from baseline in mean body mass 
index
Mean change in waist circumference
Biomarkers
European Quali ty of Life -dimensions 
(EQ-5D-5L) scores
Abbreviatio ns:  HbA1c =hemoglobin A1c; HDL=high density lipoprotein; QW =once weekly; T2DM = type 2 
diabetes mellitus ; TG=triglycerides; VLDL =very low density lipoprotein
I8F-MC-GPG H(c) Clinical Protocol Page 27
LY32981765.Study  Design
5.1. Overall Design
Study  GPGH i s a Phase 3, multicenter, randomized, open -label, parallel -group study  that will  
investigate the effects of treatment with LY3298176 5 mg, 10 m g, and 15 m g QW com pared 
with titrated insulin degludec in patients with T2DM who have inadequate glycemic control on 
stable doses of metformin ,with or wi thout an SGLT -2i.  The primary endpoint will be the mean 
change in HbA1c from baseline to 52 weeks. 
Patients shoul d be on a stabl e dose (no dose change for at least 3 months )metformin alo ne or 
metformin plus a
nSGLT -2i.  Pati ents will  be randomized in a 1:1:1:1 ratio ( LY3298176 5 mg 
QW, 10 m g QW, 15 m g QW, orinsulin degludec once daily [QD]).  Patients will be stratified at 
rando mizat ion based on HbA1c ( ≤8.5%, >8.5% [69 mmo l/mol]), country , and use of 
concomitant oral ant idiabet ic treatments (metformin alo ne, m etformin plus an SGLT -2i).
Insulin degludec will be injected QD, as a single SC inject ion, ideally at bedt ime at 
approximately  the same t ime every n ight.  The init ial dose will be 10 IU/day  and will  be adjusted 
weekly per a treat-to-target (TTT) algorithm, based on the last 3fasting blood glucose (FBG) 
values.
Study  governance considerations are described in detail in Appendix 3 .
Figure GPGH .1illustrates th e study  design.
I8F-MC-GPG H(c) Clinical Protocol Page 28
LY3298176Abbreviations:  F BG = fasting blood glucose; QD =once daily; QW =once weekly; 
SGLT -2i = sodium -glucose co -transporter -2 inhibitor; TTT =treat to target.
aStable doses of metformin ( ≥1500 mg/day) ± SGLT -2ifor ≥ 3 mo nths prio r to 
Visit 1 and during the screening/lead -in period.
bThe starting dose of insulin degludec will be 10 IU/day ideally at bedtime, 
titrated to a F BG <90 mg/dL, following a TTT algorithm .  
Figure GPGH .1. Illustration of study design for Clinical Protocol I8F-MC-GPGH .
Study Period I ( Screening and Lead-in)
Screening (Visit 1)
The purpose of screening procedures at Visit 1 is to establish init ial eligibili ty and to obtain 
blood sam ples for l aboratory  assessments needed to confirm eligibilit y at Vi sit 2.The patient 
will sign the informed consent form (ICF) before any study  procedures are performed .  
Procedures at this visit will be performed as sh own in the Study  Schedule of Act ivities, 
Secti on2.Patients who meet all applicable inclusion criteria and none o f the applicable 
exclusio n criteria (Section 6) at Vi sit 1 will  continue on thei r prestudy  therapy  between Visi ts1 
and 2. 
Lead- in (Visit 2 to Visit 3)
At Visit 2, the screening laboratory  resul ts will  be reviewed .For those patients meet ing all other 
eligibilit y requi rements, a dilated fundoscopic exam ination performed by  anophthalmo logist or 
optom etrist ,must be completed between Visit 2 and Visit 3 to ensure that 
patients wit h 
proliferat ive diabet ic retinopathy ,diabetic maculo pathy ,or nonproliferat ive diabet ic retinopathy  

I8F-MC-GPG H(c) Clinical Protocol Page 29
LY3298176who require acute treatment, are ident ified and not enro lled. Addit ionally, at Vi sit2, pati ents 
and their caregiver(s), if applicable, will receive a glu cometer and training on how to perform 
self-monitoring of blood glucose (SM BG).  The SM BG plan will  include daily  measurements of 
FBG, one weekly 4- point BG profile and two 7 -point SM BG profiles done on 2 nonconsecut ive 
days in the 2-week period prior to Visit 3 (rando mization), Visit 17 (Week 24), Visit 19 (Week 
40) and Vi sit 21(end of treatment).  Patients will be provided diaries and will be trained as 
appropriate to record BG values, hypoglycemic events .During this period, patie nts will also be 
trained on disease management and study  procedures; thi s training can be repeated at subsequent 
visits as deemed appropriate. During the lead -in peri od, pati ents shoul d continue thei r prestudy  
therapy  and shoul d not change the ty pe of OAM s used or their doses
,in order to allow reliable 
assessment of HbA1c at baseline (Visit 3).  If patients develop a condit ion that i s a 
contraindicat ion for the use of OAMs, they  will be consi dered ineligible and must be 
discontinued fro m the trial before rando mizat ion.  
Study Period II (52-Week Treatment Period )
Randomization (Visit 3)
At Visit 3, eligible patients will perform all required baseline study procedures (including the 
collect ion of all baseline laboratory measures) prior to randomization and prior to taking the first 
dose of study  drug.  Patient should arrive to the clinic in the fast ing state; the fast ing state should 
have lasted at least 8 hours without having taken any doses of their study  drug, m etformin and 
SGLT -2i(if used). The questionnaires (European Qualit y of Life [ EQ-5D-5L] , Abilit y to 
Perform  Physical  Activi ties of  Daily Living [APPADL ], Impact of  Weight on Self -Percept ion
[IW-SP], and Diabetes Treatm ent Satisfaction Questionnaire status [DTSQ s]) should be 
completed before any other study  procedures if the pati ent is not adversely  affected by  the 
fasting condit ion or com pleted after the patient has sufficient ly recovered from the preceding 
visit procedures. 
During the first 4 weeks ,patients assigned to groups receiving LY3298176 QW will administer 
LY3298176 2.5 m g QW subcutaneously.  Patients will be instructed on how to use the 
single -dose pen (SDP) and will inject their first dose of LY3298176 while in the clinic for Visit 
3.  Patients random ized to the insulin degludec group will be trained on how to use the 
FlexTouch device and will administer insulin degludec once daily  ideally at bedtime. The date 
and time o f the first dose of study  drug shoul d be recorded on the electroni c case report form 
(eCRF).
Following rando mizat ion, pati ents will  parti cipate in a 52 -week treatment period.  
Postrandomization period (end of Visit 3 to Visit 21):
The starting dose of LY3298176 will be 2.5 mg QW for 4 weeks, followed by an increase to 
5mg QW, for th e durat ion of the study  in the 5 mg group .  For the 10
-mg group , the starti ng 
dose of LY3298176 will be 2.5 mg QW for 4 weeks, then the dose will be increased by 2.5 mg 
every 4 weeks (2.5 to 5 to 7.5 to 10 mg) unt il the 10 -mg dose is reached and maintained for the 
durati on of  the study .  For the 15 -mg group , the starti ng dose of LY3298176 will be 2.5 mg QW 
I8F-MC-GPG H(c) Clinical Protocol Page 30
LY3298176for 4 weeks, then the dose will be increased by  2.5 mg every  4 weeks (2.5 to 5 to 7.5 to 10 to 
12.5 to 15 mg) unt il the 15 -mg dose is reached and maintai ned for the duration of the study .  
The init ial dose of insulin degludec will be 10 IU/day  ideally  at bedt ime, titrated to a FBG 
<90mg/dL, fo llowing a TTT al gorithm (Philis -Tsimikas et al . 2013; Pan et al. 2016; Aroda et al. 
2016) (see Section 7.2.1.2 , Table GPGH. 4).
Most of the insulin degludec titration should occur during the first 16 weeks of the study , 
followed by a 36- week maintenance peri od.  The maintenance period is defined as a part of the 
titration period when the insulin degludec dose is expected to be stable and optimized (Weeks 
16-52 [Vi sits 15-21 ]).
During the first 8 weeks ,the insulin degludec dose adjust ment will be determined by  the 
investigator in discussio n with the pati ent and thi s time will be used as preparation and training 
for implementati on of  the pati ent self -titration according to the TTT algorithm ( Section 7.2.1.2 , 
Table GPGH. 4).  After Week 8, the decisio n of the titration will be made and implemented by 
the pati ent in a weekly  manner.  Between Week 8 and Week 1 6, invest igators or study site 
personnel will contact the patient every  2 weeks (office or telephone visit) and will review the 
insulin dose adjust ment made by the patient at each of th esevisits.  Invest igators may perform 
additional telephone visit s if necessary , or perf orm addi tional office visit s if the invest igator 
deems addit ional training is necessary .
During the treatment period, office visits will occur weekly or every other week during the first 
16 weeks, and thereafter, every
 4 to 8 weeks to enable the site to properly  monitor pati ents’ 
usage of the TTT algorithm.
At each of the 6scheduled telephone visits, procedures will include assessments of SMB G, 
compliance wi th insulin t itration algorithm, insulin dose, LY3298176 compliance (will be 
re-assessed at the office visit), hy poglycemic events, concomitant medicat ions, and AEs (see 
Schedule of ActivitiesSection 2).  The data obtained at these telephone visits will be entered into 
the eCRFs at the next office visit.  
Throughout the treatment period, patie nts will collect all data on SMB G, insulin dose
assessments, insulin doses administered, dates when study  drug was administered, hy poglycemic 
events, in the patient diary to be reviewed with the study  site personnel at the next office visit.  
For that purpose, at each visit, study  diaries f or the peri od after the previous office visit ,will be 
collected, and instructions will be reviewed at each visit.  Study  drug and inject ion supplies will 
be returned per the Schedule of Act ivities (Secti on2) and according to local requirements.  New 
supplies will be dispensed as needed.  
Results of SMB G and hypoglycemic events will be used by  the pat ient to assess insulin degludec 
doses per the TTT algorithm. Insulin degludec dose assessments must be performed once per 
week (see Section 7.2.1.2 ).  Addit ional assessments m ay be requested by  the invest igator based 
on his/her clinical judgment. Outcome of the assessment will be recorded in pat ient diaries.
Com pliance wi th the LY3298176 administration schedule and compliance with the insulin 
degludec T TTalgorithm will be assessed at every  office visit and collected in the eCRF at
I8F-MC-GPG H(c) Clinical Protocol Page 31
LY3298176prespecified visits ( Secti on 2).Based on the outcome of these re views, the site staff should 
discuss additional insulin degludec dose adjustments while the patient is st ill at the site and 
provi deretraining, if n eeded.
Patients shoul d be instructed to con tact the invest
igative site for assistance as soon as possible if 
they experience any  difficul ties administering their study  medicati on or wi th the TTT al gorithm 
at any  time during the study  treatm ent peri od. Patients s hould also be advised about the 
appropriate course of action in the event that study drug is not taken at the required t ime 
(late/missing doses) .
Study Period I II(Safety Follow -up Period )
Safety follow -up (Visit 801) v isits:
All patients who complete the treatm ent peri od are requi red to com plete Vi sit801, a safety  
follow
-up visit ,approximately  4weeks after their last visit.  Patients discont inuing the study 
early  and performing an early terminat ion (ET) visit will also be asked to perform the safety  
follow-up visit, so that the safet y follow-up visi t will  be thei r final  visit.  During the safet y 
follow-up period, patients will not receive study  drug.  Pati ents will be treated with another 
glucose -lowering intervent ion decided upon by the invest igator.  Initiation of  new 
antihyperglycemic therapy for the safety follow-up period will not be classified as “rescue 
therapy .
”Patients are also required to return any remaining study  diaries to the study  site at the 
end of this period.
Study Procedures
Patients will perform study  procedures listed in the Schedule of Activit ies (Secti on2).  
Patients will  be permitted to use concomitant medications that th ey requi re during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatm ents.  Antihyperglycemic medicat ions other than study  drugs 
are not allowed at any  time during the stud y except as allowed for rescue therapy  and/or after 
early  study  drug discont inuat ion.  Rescue therapy  with other gl ucose -lowering agents, including 
prandial insulin, may be medically  indicated in certain situat ions after randomization due to
severe, persis tent hyperglycemia or early discont inuation of study  treatm ent.  Glucagon -like 
pepti de-1 receptor agoni sts, di peptidyl pept idase (DPP -4) inhibitors, and pramlint ide are 
prohibited medicat ions and are not allowed as rescue t herapies .  No other basal insulin s are 
allowed during the course of the study  (except for LY3298176 groups ).
Patients who develop severe, persistent hy perglycemia based on prespecified thresho lds (see 
Secti ons 7.2.1.2 and 9.2.2.2 ) will receive a new glucose -lowering intervent ion (“rescue therapy”) 
and will also continue to administer study  drug.  Pati ents who need hyperglycemic rescue 
therapy  will cont inue in the study until they co mplete all study  visit s.  
Study  governance considerations are described in detail in Appendix 3 .
I8F-MC-GPG H(c) Clinical Protocol Page 32
LY32981765.2. Number of Participants
A total o f approximately  1420 pat ients will be randomized in a 1:1:1:1 ratio to receive 
LY3298176 doses:  
5 mg QW (355 pati ents), 
10 m g QW (355 patients),
15 m g QW (355 pati ents), or
insulin degludec QD (355 patients).
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last patient .
5.4. Scientific Rationale for Study Design
Study  GPGH i s designed to determine the comparative benefit s and risks of QW LY3298176
5mg, 10 mg, or 15 mg versus insu lin degludec in patients with T2DM who have inadequate 
glycemic control on stable doses of met formin wit h or wi thout an SGLT -
2i.
An act ive co mparator rather than placebo was selected for this study  because it includes patients 
with uncontrolled T2DM despite use of oral antihyperglycemic therapies ( HbA1c 7.0% [53 
mmo l/mol] to 10.5% [91 mmo l/mol], inclusive).  Insulin degludec was selected as the 
comparator because it is a widely  used therapy  prescrib ed in this pat ient population , with similar 
efficacy  to insulin glargine while providing benefit s in term s of hypoglycemia (Vora et al. 2015, 
Ratner et al. 2013 ).  Metformin and SGLT -2i were chose n as the concomitant ant ihyperglycemic 
medicat ion as they  are comm only used in clinical practice , also in combinat ion,and its use in 
patients who init iate insulin therapy  is frequent and the ri sk of hypoglycemia is low .  To ensure a 
valid co mpar ison of the rando mized study treatments, it is important that insulin degludec is 
titrated optimally  throughout the ent ire study.  Patients will  be requi red to use a TTT al gorithm, 
which has been shown to be effective in enabling a high proportion of pat ients with T2DM to 
achieve their therapeutic targets when treated with insulin degludec (Philis -Tsimikas et al. 2013, 
Pan et a l. 2016, Aroda et al. 2016) as described in Section 7.2.1.2 .  The frequency o f clinic and 
telephone visits postrandomizat ion is intended to allow patients and investigators frequent 
assessment of study  treatments, including optimal insulin degludec do se adj ustments as needed 
for the attainment of glycemic goals wit hin a short time period.  
The parallel -group desi gn for treatment com parison was chosen to avoid any interaction between 
treatm ents that m ay interfere with the interpretation of the study  outcome.  To minimize the 
potenti al conf ounding effect of changes to concomitant medications, patients will be permitted to 
use concomitant medicat ions that they  requi re during the study .  Medicat ions that may interfere 
with the assessment of efficacy  and sa fety characteri stics of the study  treatm ents will  not be 
allowed (see Section 7.7).  An open -label design was chosen due to the different dosing 
frequenc y,titrationscheme and inject ion device of insulin degludec compared with LY3298176.
I8F-MC-GPG H(c) Clinical Protocol Page 33
LY3298176The pl anned durat ion of treatment for the primary endpo int at 52 weeks is considered appropriate 
to assess the full effects and benefit/risk of each maintenance dose of LY3298176 on both 
glycemic control and body  weight.  Moreover, the duration of the study is considered sufficient 
and appropriate for patients to optimize dosing of insulin degludec for comparison with the 
LY3298176 treatm ent groups wi th respect to change in HbA1c. 
5.5. Justification for Dose
LY3298176 doses of 5 mg, 10 mg, and 15 mg administered subcutaneously QW will be 
evaluated in this study . 
These doses and associated escalat ion schemes were selected based on assessment of safet y, 
efficacy  (glycem ic and weight loss benefit), and GI tolerabilit y data fo llowed by  exposure 
response modeling of data in patients wi th T2DM in Phase s1 and 2 studies.  Dosing algorithms 
starting at a low dose of 2.5 mg acco mpanied by dose escalat ion of 2.5 m g increments ev ery 
4-week would permit time for development of tolerance to GI events and are predicted to 
minimize GI tolerabilit y concerns.
The m aximum  proposed dose of 15 m g maintains an exposure mult iple of 1.6 to 2.4 to the 
no-observed adverse effect level doses in 6-mont h monkey and rat toxico logy studi es.
The selected dose and escalation scheme woul d enable further evaluat ion of benefit/risk 
considerations for 5 mg, 10 mg, and 15 mg doses of LY3298176 .
I8F-MC-GPG H(c) Clinical Protocol Page 34
LY32981766.Study  Population
Prospective approval o f protocol  deviati ons to recruit ment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all of the f ollowing criteria at 
screening :
Type of Patient andDisease Characteristics
[1] Have been diagnosed with T2DM based on the W orld Health Organizat ion
classificat ion or other locally applicable diagnostic standards
Patient Characteristics
[2] Have HbA1c ≥7.0% (53 mmo l/mol) to ≤10.5% (91 mmo l/mol), as determ ined by  
the central  laboratory  at Vi sit 1
[3] Are insulin -naive (except for the use of insulin for treatment of gestational 
diabetes or short -term use [14 days] for acute condit ions)
[4] Are on stable diabetes treatment with met formin or metformin plus anSGLT -2i
(metformin ≥1500 m g/day and no m ore than the maximum approved dose per 
country -specific l abel) for at l east 3 m onths pri or to Visit 1 and between Visit 1 
and Visit 3
[5] Are of stable weight (±5%) ≥3 months prior to Visit 1 and agree to not initiate a 
diet and/or exercise program during the study with the intent of reducing body 
weight other than the lifest yle and dietary measures for diabetes treatment
[6] Have body  mass index ≥25 kg/m2at Vi sit 1
[7] Are 18 y ears ol d or of an acceptable age to provi de informed consent according to 
local regulati ons, whichever is older
Male patien ts(see Appendix 6 for more details) :
Male patients should be willing to use reliable contraceptive methods throughout 
the study  and f or at least 3 m onths after l ast inject ion 
Female pat ients:
Female pat ients not of childbearing potential due to surgical sterilizat ion 
(hysterectomy or bilater al oophorectomy  or tubal  ligat ion), congenital ano maly 
(i.e.Mullerian agenesis) or menopause.
oWomen with an intact uterus are deemed postmenopausal if they are at 
least 45 years ol d, and
have not taken hormones or oral contraceptives within the last y ear 
and had cessat ion of menses for at least 1 y ear,
OR
I8F-MC-GPG H(c) Clinical Protocol Page 35
LY3298176have had at least 6 months and l ess than 12 m onths of spontaneous 
amenorrhea wi th follicle-stimulat ing hormone (FSH) and estradio l 
levels consistent with a postmenopausal state (FSH ≥ 40 m IU/mL 
and estradi ol <30 pg/m L).
oFemale pat ients of child -bearing potenti al (not surgi cally sterilized and
between m enarche and 1 -year postm enopausal ) must:
test negative for pregnancy  at Vi sit 1 based on a serum  pregnancy 
test
AND
if sexually  active, agree to use two forms of effect ive 
contraception, where at least one form is highly effective for the 
durati on of  the tri al and for 30 day s thereafter 
not be breastfeeding
[8] In the invest igator’s opinio n, are well -motivated, capable, and willing to: 
(a) perform  fingerst ick BG mo nitoring, including scheduled BG profiles wit h up to 7 
measurements in 1 day  
(b) learn how to self- inject treatm ent (LY3298176 or insulin degludec), as required for 
this protocol  (visually  impaired persons who are not able to perf orm the inject ions 
must have the assistance of a sighted individual trained to inject the study drug; 
persons with physical limitat ions who are not able to perform the injections must 
have the assistance of an individual trained to inject the study  drug) 
(c) are willing and able to inject LY3298176 QW or insulin degludec QD
(d) maintain a study  diary , as requi red for this protocol
(e) have a sufficient understanding of one of the provided languages of the country  
such that they  will be able to com plete the patient questionnaires
Informed Consent
[9] Have given written informed consent to participate in this study  in accordance 
with local regulat ions and the Ethical R eview Board (ERB) governing the study  
site
6.2. Exclusion Criteria
Patients will be excluded fro mstudy  enro llment if they meet any o f the following cri teria at
screening :
Medical Conditions
[
10] Have t ype 1 diabetes mellitus (T1DM)
[11]Had chronic or acute pancreatit is any t ime prior to study entry (Visit 1)
[12]Have history  of:
I8F-MC-GPG H(c) Clinical Protocol Page 36
LY3298176proliferat ivediabe ticretinopathy  
or 
diabetic maculopathy 
or
nonpro liferat ive diabet ic retinopathy that requires acute treatment
(adilated fund oscopic examinat ion performed by a nophthalmo logist or
optom etrist between Visit 2 and Visit 3 is required to confirm eligibili ty)
[13]Have a history  of severe hypoglycemia and/or hy poglycemia unawareness within 
the 6 m onths pri or to Vi sit 1
[14]Have a history  of ketoaci dosis or hy perosm olar state/com a 
[15]Have a known clinically significant gastric empt ying abnormal ity (for example, 
severe diabet ic gastroparesis or gastric outlet obstruction), have undergone or 
plan to have during the course of the study :  a gastric bypass (bariatric) surgery  
or restri ctive bariatric surgery (for example, Lap -Band®), or chroni cally t ake 
drugs that direct ly affect GImotility
[16]Have any of the fo llowing CV condit ions wi thin 2 m onths prior to Vi sit 1:  acute 
myocardial  infarct ion, or cerebrovascular accident (stroke) or hospitalization due 
to congestive heart failure (CHF)
[17]Have New York Heart Associat ion Funct ional Classification III and IVCHF
[18]Have acute or chronic hepat itis, signs and symptoms of any other liver disease 
other than nonalcoho lic fatty liver disease (NAFLD), or alanine aminotransferase 
(ALT) level >3.0 times the upper limit of the reference range, as determined by  
the central  laboratory  at study  entry; patients with NAFLD are eligible for 
participat ion in this trial only if thei r ALT level  is ≤3.0times the upper limit of 
norm al (ULN )for the reference range
[19]Have an est imated glomerular filtration rate <45 mL/min/1.73 m2(or lower than 
the country -specific thresho ld for using the protocol -requi red dose of m etformin 
per local label), cal culated by  Chronic Kidney Disease -Epidemi ology, as 
determined by centr al laboratory  at Vi sit 1
[
20] Have evidence of a significant, uncontrolled endocrine abnormalit y (for 
example, thy rotoxi cosis or adrenal crises), in the opinio n of the investigator
[21]Have family or personal history  of medullary thy roid carcino ma (MTC) or 
multiple endocrine neoplasia syndro me type 2
[22]Have a serum calcitonin level of ≥35 ng/L , as determined by central laboratory  at 
Visit
1
[23] Known or suspected hy persensi tivity to trial product(s) or related products
[24]Have evidence of a signifi cant, active autoimmune abnormalit y (for example, 
lupus or rheumatoid arthrit is) that, in the opinion of the invest igator, is likely to 
requi re concurrent treatment with systemic glucocorti coids in the next 12months
I8F-MC-GPG H(c) Clinical Protocol Page 37
LY3298176[25] Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or 
awaiting an organ transplant
[26]Have a history  of an act ive or untreated malignancy or are in remissio n from a 
clinically significant malignancy (other than basal or squamous cell skin cancer, 
in situ carci nomas of the cervix, or in situ prostate cancer) for less than 5 y ears
[27]Have a history  of any other condit ion (such as known drug, alcoho l abuse, or 
psychiatric disorder) that, in the opinion o f the investigator, may preclude the 
patient from following and co mpleting the protocol
[
28] Have any hematological condit ion that m ay interfere with HbA1c measurement 
(for example, hemo lytic anemias and sickle cell disease)
Prior/Concomitant Therapy
[29]Treatment with any glucose -lowering agent(s) other than sta ted in the inclusio n 
criteria [4 ] in a period of 3 months prior to Visit 1 and between Visit 1 and 
Visit
3
[30] Have been treated with prescription drugs that promote weight loss (for exam ple, 
Saxenda [liraglut ide 3.0 mg], Xenical®[orlistat], Meridia®[sibutramine], 
Acutrim®[phenylpropano lamine], Sanorex®[mazindo l], Apidex®[phentermine], 
BELVIQ®[lorcaserin], Qsymia™[phentermine/topiramate combinat ion], 
Contrave®[naltrexone/bupropion], or similar other body  weight l oss medicat ions 
including over -the
-counter medicat ions [for example, allī®]) wi thin 3 m onths 
prior to Visit 1 and/or between study  entry  (Visi t 1) and randomizat ion (Vi sit 3)
[31]Are receiving chronic (>2 weeks or 14 day s) systemic glucocortico id therapy 
(excluding topical, intraocular, int ranasal, or inhaled preparations) or have 
received such therapy  within 1 m onth of Visit 1 or between Visit s 1 and 3
Prior/Concurrent Clinical Trial Experience
[
32] Are current ly enrolled in any other clinical study  involving an invest igational 
product or any other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
[33] Have part icipated, within the last 30 days in a clinical study  involving an 
investigat ional product.  If the previous investigational product ha s a long 
half-life, 5 half -lives or 30 day s (whichever i s longer) shoul d have passed
[
34] H ave previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ing LY3298176
Other Exclusions
[
35] Are invest igator site personnel directly affi liated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted
[36] A re Lilly  empl oyees 
I8F-MC-GPG H(c) Clinical Protocol Page 38
LY3298176[37] Are unwilling or unable to comply  with the use of a paper diaryto directly 
record data from the subject
6.3. Lifestyle Restrictions
Per the Schedule of Act ivities (Section 2), qualified medical staff will prov ide diabetes 
management counseling, which will include instructions on diet and exercise and educat ion 
about the signs, symptoms, and treatment of hypoglycemia , 
shoul d it occur .  
Patients shoul d cont inue their usual exercise habits and generally fo llow a healthy meal plan 
(with consistent meal size and time of day ) throughout the course of the study .  Dietary  
counseling may be reviewed throughout the study , as needed.  Per inclusio n criterion [5] 
(Secti on6.1), patients should not init iate during the study  an organi zed diet and/or exercise 
weight reducti on program other than the lifest yle and dietary measures for diabetes treatment.
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) must not 
berescreened .  
I8F-MC-GPG H(c) Clinical Protocol Page 39
LY32981767.Treatment s
7.1. Treatments Administered
Patients will be randomized in a 1:1:1:1 ratio to receive LY3298176 5 mg,10 m g, 15 m g, or 
insulin degludec.  LY3298176 will be administered QW as SCinject ion in pat ients with T2D M
who are already treated with a stable dose of at least 1 and no more than 2 oral 
antihyperglycemic medicat ions:  metformin alone or m etformin plus sodium-glucose 
co-transporter -2 inhibitors.
Table GPGH. 3.shows the rando mized treatm ents for the ent ire treatm ent peri od.
The starting dose of LY3298176 will be 2.5 mg QW for 4 weeks, followed by an increase to 
5mg QW, for the duration of the study  for the 5 -mg group .  For the 10
-mg group , the starti ng 
dose of LY3298176 will be 2. 5 mg QW for 4 weeks, then the dose will be increased by  2.5 m g 
every 4 weeks (2.5 to 5 to 7.5 to 10 mg) unt il the 10 -mg dose is reached and maintained for the 
durati on of  the study .  For the 15 -mg group , the starti ng dose of LY3298176 will be 2.5 mg QW 
for 4 weeks, then the dose will be increased by 2.5 mg every 4 weeks (2.5 to 5 to 7.5 to 10 to 
12.5 to 15 mg) unt il the 15 -mg dose is reached and maintained for the duration of the study .  
The starting dose of insulin degludec will be 10 IU/day  at bedtime, t itrated to a F BG <90mg/dL, 
following a TTT algorithm ( Philis -Tsimikas et al .2013, Pan et al .2016, Aroda etal. 2016).  
Patients w ill titrate the insulin degludec dose in a weekly manner and will make the dose 
decisio n with the investigator for the first 8 we
eks (phone or clinic visit).  For further dose 
titration, from Week 8 to Week 16, patients will have a phone or clinic visit every  other week.
Table GPGH. 3. Study Treatment s
Name of Drug Dosage Frequency Drug 
FormulationRoute of 
Administration
Investig ational Compound
LY3298176 5 mga QW S ingle -dose pen SC
10 mgaQW Single -dose pen SC
15 mgaQW Single -dose pen SC
Comparator s
Insulin degludec TTT dosing b QD FlexTouch 
pre-filled pencSC
Abbreviations:  QD =once daily; QW =once weekly; SC =subcutaneous; TTT =treat-to-target .
I8F-MC-GPG H(c) Clinical Protocol Page 40
LY3298176aThe starting dose of LY3298176 will be 2.5 mg QW for 4 weeks, followed by an increase to 5 mg QW, for the 
duration of the study for the 5 -mg group.  For the 10 -mg group , the starting dose of LY3298176 will be 2.5 mg 
QW for 4 weeks, then the dose will be increased by 2.5 mg ever y 4 weeks (2.5 to 5 to 7.5 to 10 mg) until the 
10-mg dose is reached and maintained for the duration of the study.  For the 15 -mg group , the start ing dose of 
LY3298176 will be 2.5 mg QW for 4 weeks, then the dose will be increased by 2.5 mg every 4 weeks (2.5 to 5 to 
7.5 to 10 to 12.5 -
15 mg) until the 15 -mg dose is reached and maintained for the duration of the study.
bThe starting dose of insulin degludec will be 10 IU/day ideally at bedtime, titrated to a F SG ≤90 mg/dL, 
following a TTT algorithm.  Insulin dose adjustments will be made in Study Period II per the TTT algorithm.
c    Prefilled device containing 3 mL(U100/ mL).
The invest igator or his or her designee is responsible for the following:
Explaining the correct use of study  drugs to the patient or patient representative, 
and SDP or insulin degludec (Tresiba) FlexTouch training. For the SDP a 
demonstrati on device will be used.
Explaining the correct u se of concomitant metformin and SGLT -2i(if used) to the 
patient, including any  contraindicat ions and appropriate dosing per 
country -specific l abeling 
Verifying that instructions are fo llowed properly
Maintaining accurate records of invest igational product dispensing and co llection
Patients shoul d return all  study  drugs to the si te according to the Sch edule of Activities, 
Secti on2.  Pati ents shoul d be instructed to discard all used SDPs and insulin degludec (U100) 
FlexTouch in a closeable, puncture -resistant container according to local regulat ions.
7.1.1. Packaging and L abeling
The sponsor will provi de LY3298176 in SDPsand ins ulin degludec (Tresiba U100) in prefilled 
pens.  These will be dispensed via an interact ive web -response system (IWRS).  Single dose pens 
and prefilled pens will be packaged in cartons to be dispens ed.  Clinical study  materi als will be 
labeled according to the coun try’s regulatory  requirem ents.
7.1.2. Medical Devices 
The combinat ion products provided for use in the study  are LY3298176 investigat ional 
single- dose pen and a m arketed insulin degludec prefilled pen.
7.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to 1 of the study  treatm ent 
groups at Visit 3.  Assignment to treatment groups will be determined by a co mputer -generated 
rando m sequence using an IWRS.  Patients will be randomized in a 1:1:1:1 ratio to receive 
LY3298176 5mg, 10mg, 15 m g, or i nsulin degludec .  
7.2.1. Selection and Timing of Doses
7.2.1.1.
LY3298176
Assignment to LY3298176 (3 doses) or insulin degludec will occur at randomizat ion.  
I8F-MC-GPG H(c) Clinical Protocol Page 41
LY3298176There are no restrict ions on the time of day  each weekly dose of LY3298176 is given, but it is 
advisable to administer the SCinjections on the same day and same time each week.  The actual 
date and time of all dose administr ations will be recorded by  the pati ent.  If a dose of 
LY3298176 is missed, the patient should take it as soon as possible unless it is within 72hours 
of the next dose, in which case, that dose should be skipped and the next dose should be taken at 
the app ropri ate time.  
7.2.1.2. Insulin Degludec
Dosing for patient s randomized to insulin degludec will start at 10 units once daily .Patients 
shoul d administer thei r daily doses at the time of day  agreed upon between the patient and the 
investigator, ideally at bedtim e.  Pati ents assigned to the insulin degludec treatm ent group will be 
instructed to adjust insulin degludec doses to a target FBG of < 90mg/dL ( 5.0mmo l/L) based on 
the median value o f the last 3 SMBG values accordin g to the schedule below ( Philis -Tsimikas et 
al.2013, Pan et al .2016, Aroda et al. 2016).   Insulin degludec dose adj ustments should occur 
once a week.  During the first 8 weeks , pati ents will titrate the dose of insulin degludec together 
with the invest igator per the titration algorithm; the insulin degludec dose will be also reviewed 
and revised, as needed, at subsequent office visit s (see Table GPGH. 4). If a dose of insul in 
degludec is missed, the patient should wait unt il the next schedule d
dose, and not inject twice on 
the sam e day .  Add-on glycemic rescue therapy  shoul d be considered for pati ents who met 
prespecified criteria for severe, persistent hyperglycemia .(seeSection9.2.2.2 ).
Table GPGH. 4. Titration of Insulin Degludec
Abbreviation:  SMBG =self-monitored blood glucose .
a  If only 2 prebreakfast SMBG values are available, the average of these 2 values will be used .  If only one 
prebreakfast SMBG value is available, the patient should contact the investigator site for instructions on adjusting 
insulin dose
Dose should also be decreased by 2 to 4 units in the following situations:
If multiple episodes of nonsevere hypoglycemia were recorded during the assessment period at any time 
during the day; and/or
If at least 1 episode that met the criteria for severe hypoglycemia (events requiring assistance to administer 
therapy ) or was associated with SMBG value <5 4mg/dL (<3. 0mmol/L) was recorded during t he 
assessment period.
If only 1 hypoglyc emic episode with SMBG value ≥54mg/dL ( ≥3.0 mmol/L) and ≤70 mg/dL (≤3.9 mmol/L) was 
recorded, insulin dose should not be changed .
Adapted from :  Philis -Tsimikas et al. 2013, Pan et al. 2016, Aroda et al. 2016 .Median of 3 Prebreakfast SMBG ValuesaAdjustment:  Units
≤70mg/dL (≤3.9 mmol/L) Decrease by 2to 4units 
71to 90 mg/ dL (4.0to 5.0 mmol/L) No adjustment
91to 126 mg/ dL (5.1to 7.0 mmol/L) Increase by  2 units
127to 144 mg/ dL (7.1to 8.0 mmol/L) Increase by  4 units
145to 162 mg/ dL (8.1to 9.0 mmol/L) Increase by  6 units
>162 mg/ dL (>9.0 mmol/L) Increase by  8 units
I8F-MC-GPG H(c) Clinical Protocol Page 42
LY32981767.3. Blinding
This trial is an open -label study  due to the differences in dosing schedule, t itration, and devices 
between once -weekly LY3298176 and QDinsulin degludec.
7.4. Dosage Modification
7.4.1. Study Drugs
Details about dose administration of LY3298176 during the st udy are described in Sections 7.2.1
and8.1.2 .
Insulin degludec will be adjusted according to the TTT method (see Secti on 7.2.1.2 Table 
GPGH. 4).
7.4.2. Reduction and/or Discontinuation of Concomitant 
Antihyperglycemic Medications
After rando mizat ion, discont inuat ion of metformin or SGLT -2i (if used) or change in dosage is 
not permitted, except in the fo llowing si tuations:
1)In the event of a hypoglycemic episode(s) (clinica l symptom s of hypoglycemia and/or 
BG-confirmed symptomat ic hypoglycemia [glucose concentration ≤3.0mmo l/L 
{54mg/dL }]):
Patients in the LY3298176 groups on dual  oral treatm ent of  metformin and SGLT -2i 
may reduce /discont inue the dose of either metformin or SGLT -2i.When 
hypoglycemia develops in pat ients on LY3298176 and metformin mo notherapy , the 
dose of this oral medication may be reduced or discontinued.
Patients in the insulin degludec group must adj ust the dose of insulin degludec 
following the TTT a lgorithm reco mmendations ( Secti on 7.2.1.2 ).In the event of 
recurrent hy poglycemic episodes despite reductions of the insulin dose, the 
investigator may  consider a reducti on in the dose of the OAM. In that case, patients 
on dual  oral treatment of metformin and SGLT -2i may reduce or discont inue the dose 
of either metformin or SGLT -2i.If the patient is on metformin mo notherapy , the 
dose of this oral medication may be reduced or discontinued.
2)In certain situat ions that require short -term discontinuat ion in line with the product(s) 
labeling for each respect ive country (for example ,for metformin: severe dehydrat ion, 
elective surgery, or need for radio logic exam inationinvolving IV iodinated con trast dy e).  
Once the situat ion that l edto tem porary  discont inuation of the drug resolved, treatment 
shoul d be restarted at invest igator discretion.
3)If a patient develops contraindicat ions to met formin or SGLT -2i (if used), such that the 
use of the drug is contraindicated according to the coun try-specific l abel, the drug shoul d 
be discont inued; in this case, the insulin degludec dose may need to be further adjusted.
I8F-MC-GPG H(c) Clinical Protocol Page 43
LY3298176A pat ient will be considered nonco mpliant wi th the protocol (protocol deviat ion) if he or she
changes the dose or discont inues metformin or SGLT -2i (if used) for reasons other than those 
described here. In the case of nonco mpliance that lasts >14 days during the treatment period, the 
patient will not be included in the per -protocol  (PP) analyses.
7.5. Preparation/Handling/Storage/Acco untability
The invest igator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved before use of the study  treatm ent.
ensuring that only participants enro lled in the study may receive study treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study 
treatm ents m ust be stored in a secure, environmentally  controlled, and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is respo nsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion and final disposit ion records).
The study  site must store the study  drug in a l ocked and secure environment. Please refer to the 
study  drug label for specific storage condit ions.  Pati ents will  receive insulated bags with cooling 
gel packs for use in transporting the study  drug carton from  the si te to hom e. 
Study  site staff must regul arly assess whether the patient is correctly administering the assi gned 
study  drug and storing the study  drug according to the provided instructions. 
7.6. Treatment Compliance
Study  drug com pliance will  be determined by  the foll owing: 
Study  drug administration data will be recorded by the patient and reviewed by  
the invest igator at each study visit.
The pati ents will  be instructed to return any  unused study  drug and/or em pty 
cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.
In the 3 LY3298176 treatm ent groups , as well as the insulin degludec group , treatm ent 
compliance for each visit interval is defined as taking at least 75% of the required doses of study  
drug.  Similarly, a patient will be considered significant ly nonco mpliant if he or she is judged by 
the invest igator t o have intent ionally or repeatedly  taken m ore than the prescribed amount of 
medicat ion.  
In addit ion to the assessment of a patient’s co mpliance with the study drug administration, other 
aspects of compliance wit h the study  treatments will be assessed at each visit based on the 
patient’s adherence to the visit schedule, compliance with the concomitant antihyperglycemic 
I8F-MC-GPG H(c) Clinical Protocol Page 44
LY3298176medicat ion regimen, complet ion of study  diaries, the results of home BG monitoring, and any 
other parameters the invest igator considers nec essary .
Patients consi dered to be poorly  com pliant wi th their medicati on and/or the study  procedures 
will receive addit ional training and instruction, as required, and will be reminded of the 
importance of co mplying wit h the protocol. 
7.7. Concomitant Therapy
Patients will  be permitted to use concomitant medications that they  requi re during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatm ents.
Invest igative site staff will i nform patients that they must consult with the investigator or a 
designated site staff member upon being prescribed any new medicat ions during the study .  Thi s 
may not be possible when init iated for treatment of medical emergencies, in which case ,the 
patient will inform the invest igator or a designated site staff member as soon as possible.  Any 
additional medicat ion initiated during the course of the study (including over -the-counter [OTC] 
drugs, such as paracetamo l or aspi rin) must be docum ented, and the name of the drug and the 
date(s) of administration must be recorded on the “Concomitant Medications” sect ion of the 
eCRF. 
Antihyperglycemic medicat ions other than study  drugs are not allowed at any  time during the 
study  except as allowed for rescue thera py.  Rescue therapy  with other gl ucose -lowering agents, 
including prandial insulin, may be medically indicated in certain situat ions after rando mizat ion 
due to severe, persistent hyperglycemia or early discontinuation o f study  treatm ent. 
Glucagon -like pep tide-1 receptor agonists, DPP -4 inhibitors and pramlint ide are prohibited 
medicat ions and are not allowed as rescue therapies. No other basal insulins are allowed during 
the course of the study  (except for LY3298176 groups ).
All nonstudy  medicati ons will be recorded on the eCRF at all  visits.
Nonst udy medicat ions taken by  patients who are screened but not randomized will not be 
reported to Lilly  unless an SAE or AE occurs that the invest igator believes may have been 
caused by  a study  procedure (see Table GPGH. 5).
I8F-MC-GPG H(c) Clinical Protocol Page 45
LY3298176Table GPGH. 5. Criteria for Use of Concomitant Medications that May Interfere with 
Efficacy an d Safety Assessments in Study GP GH
Abbreviations: DPP-4 = dipeptidyl peptidase -4; GLP -1 RA =glucagon -like peptide -1 receptor agonist; N =no; 
N/A = not applicable; SGLT -2i = sodium -glucose co -transporter 2 inhibitor ; Y= yes.
aAcute therapy =treatment for up to 14 days.
bIncludes Saxenda® (liraglutide 3.0 mg), Xenical ®(orlistat), Meridia ®(sibutramine), Sanorex ®(mazindol), 
Apidex ®(phentermine), BELVIQ ®(lorcaserin), Qsymia ®(phentermine/topiramate combination), Contrave ®
(naltrexone/buproprion), or similar other body weight loss medications including over -the-counter medications 
(for exa mple; allī®) within 3 months prior to Visit 1 or any time during the trial. 
cFrom 1 month sprior to Visit 1 or between Visits 1 and 3; does not apply to topical, intraocular, intranasal, 
intra-articular, or inhaled preparations. 
dSwitching metformin ma nufacturers is allowed as long as the dosage is the same.  Changing to a metformin 
formulation with a different action profile ( for example , from short -acting to long -acting metformin) is not 
permitted.
eFor rescue therapy, metformin dose can be increased if the dose is below maximum approved dose per 
country -specific label and is well tolerated.
7.7.1. Management of Patients with Gastrointestinal Symptoms
In the Phase 2 program, the most commo nly reported treatment -emergent AEs (TEAEs) for 
patients receiving LY3298176 were nausea, vo miting, and diarrhea.  
The LY3298176 dose escalation scheme has been designed to minimize the development of 
intolerable GI symptom s.  The escalat ion peri od is considered to be 24 weeks, which allows 
20week s to escalate to 15 mg and addit ional 4 weeks to reach steady  state.  During the dose 
escalat ion peri od, every  effort shoul d be made by the invest igator to be able to escalate and 
maintain patients on the corresponding study  drug dosage. 
To mit igate GI sy mptom s and m anage pati ents wi th intolerable GI AEs, the invest igator should :Drug ClassUse during
Screening/Lead -InConditions for Use after Randomization
Acute 
TherapyaRescue 
Therapy During Safety 
Follow -Up Period
Drugs with approved weight loss 
indicationb Excluded N N/A Y
Systemic glucocorticoid therapyc Excluded except for 
acute therapya Y N/A Y
Antihy perglycemia medications
Other GLP -1 RAs Excluded N N N
DPP-4 inhibitors Excluded N N N
Pramlintide Excluded N N N
SGLT -2i Allowed N Y Y
InsulinsaExcluded except for 
short term useY Y Y
Meglitinides Excluded N Y Y
Alpha-glucosidase inhibitors Excluded N Y Y
Sulphonylureas Excluded N Y Y
Thiazolidinediones Excluded N Y Y
MetformindRequired N/A Y e Y
I8F-MC-GPG H(c) Clinical Protocol Page 46
LY3298176Advise patients to eat smaller meals, for example, splitt ing 3 daily meals into 4 or 
more smaller m eals, and to stop eating when they feel full.
Prescribe symptomat ic med ication (for example, ant i-emetic or anti -diarrheal  
medicat ion) per local country  availabilit y and individual patient needs .  Use of 
symptom atic medicat ion shoul d be captured as concomitant medicat ion in the 
eCRF .
Temporarily  interrupt LY3298176 ( omit 1 dose, the patient will take 3 of 4 doses 
at that dose level) .The data related to temporary  interruption of study  treatm ent 
shoul d be docum ented in source documents and entered on the eCRF.  
After the interruption, restart at the same dose with the patient taking medication 
to alleviate their GI symptoms (Section 8.1.2 ).  
If intolerable GI symptoms or events persist despite the above measures, the invest igator may 
decide to con tinue treatm ent at a l ower, tol erated maintenance dose of LY3298176 (5 mg or 
10mg).  
Patients at 5 mg or lower will be discont inued from LY3298176 .
Patients at 7.5 mg or 10 mg will decrease the dose to 5 mg.
Patients at 12.5 mg or 15 mg will decrease the dose to 10 mg.
If de- escalat ion of the LY3298176 dose is necessary, the invest igator will use the IWRS to 
receive the appropriate LY3298176 dispensing information.  If de -escalati on is needed between 
scheduled visits, the IWRS will hav e unscheduled visit s (for example, Visit 13a) dedicated to 
provi de dispensing informat ion for pati ents whose dose has been de -escalated. Those patients ,
who have their dose de -escalated, will not be escalated again. The dose can be de -escalated only  
once.  After that, the patients will have to discont inue LY3298176 if intolerable GI AE persists.  
Please see the Manual o f Operati ons f or more detailed instructions.
If intolerable persistent GI symptoms occur after Week 24, the invest igato r should take the above 
measures to keep the patient on study  treatm ent. However, after the escalat ion peri od 
(Week 24), dose decreases will not be allowed.
7.8. Treatment after the End of the Study
7.8.1. Treatment after Study Completion 
Study  com pletion will occur after all patients compl etethe follow-up visit.   Invest igators will 
continue to fo llow Schedule of Act ivities (Section 2) for all  patients until notified by Lilly that 
study  com pletion has occurred.
LY3298176 willnot be made available after conc lusion of the study  to pati ents.
7.8.2. Special Treatment Considerations 
Invest igators will be trained on how to apply decisio n criteria for the timing a nd method of 
intervent ion in patients who do not reach glycemic targets during the treatment period.  An 
additional therapeuti c intervent ion should be considered for patients with persistent 
hyperglycemia as described in Sect ion9.2.2.2 .
I8F-MC-GPG H(c) Clinical Protocol Page 47
LY32981768.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of invest igational product:
Patient Decision
oThepatient requests to discont inue invest igational product.
Discontinuation due to a hepatic event or liver test abnormality .  Patients who are 
discontinued fro m invest igational product due to a hepat ic event or l iver test abnormalit y 
shoul d have addi tional hepatic safet y data collected via the eCRF .
Discontinuati on of  the invest igational product for abnormal liver tests should be
considered by the investigator when a patient m eets one of the fo llowing condi tions a fter 
consultation wit h the Lilly -designated m edical monitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o (INR) >1.5 
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
alkaline phosphatase (ALP) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigu e, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, pati ents will  be discont inued fro m the investigat ional product in the 
following circumstances:
If a patient is inadvertent ly enro lled and it is det ermined that continued treatment 
with study  drug woul d not be m edically  appropri ate, see Section 8.1.3
Acute or chronic p ancreat itis 
If a patient is diagnosed with MTC after randomization ,orhas a
postrandomizat ion calcitonin value ≥35 ng/L thathas increased at least 50% over 
baseline
If a patient i s diagnosed wi th an active or untreated malignancy  (other than basal 
or squam ous cell skin cancer, in situ carcino mas of the cervix, or in situ prostate 
cancer) after randomization
Any significant study  drug -related hypersensit ivity reacti on
I8F-MC-GPG H(c) Clinical Protocol Page 48
LY3298176Any o ther TEAE, SAE, or clinically significant laboratory  value for which the 
investigator believes that permanent study  drug di scontinuat ion is the appropriate 
measure to be taken
Iffemale pat ient beco mes pregnant
If a patient is diagnosed with T1DM
Patients who stop the study  drug permanent ly will receive another glucose -lowering intervention
(Secti on 7.4.2 ) and will cont inue participating in the trial according to the protocol to collect all
planned efficacy  and safet y measurements.
Patients di scont inuing fro m the invest igational product premat urely for any  reason shoul d 
complete AE and other fo llow-up procedures per Section 2Schedule o f Activities, Secti on 9.2
Adverse Event , and Section 9.4Safet yof this protocol .
8.1.2. Temporary Discontinuation from Study Treatment 
In certain situat ions after rando mizat ion, the investigator may need to temporarily interrupt study  
drug.  Every effor t should be m ade by  the invest igator to m aintain pat ients on study  drug and to 
restart study  drug after any  temporary  interruption, as soon as it is safe to do so.  
For pati ents assigned to LY3298176:
If the number of doses missed is ≤2, the treatment can be restarted at the same dose, if the 
drug was well tolerated prior to discont inuat ion.
If the number of missed doses is ≥3, then the treatment should be restarted at 5 mg 
irrespect ive of the dose the patient was receiving before the interruption and subs equent ly 
escalated as required by protocol (See Manual o f Operati ons for further details) .
If study  drug interrupti on is due to an AE, the event is to be documented and fo llowed according 
to the procedures in Section 9.2of this protocol.  If the study  drug interrupti on is due to 
intolerable persistent GI AE (for example, nausea, vomit ing, or diarrhea), the patients should be 
treated as suggested in S ection 7.7.1 .
The data related to temporary  interrupti on of  study treatm ent will  be docum ented in source 
docum ents and entered on the eCRF.
8.1.3. Disconti nuation of Inadvertently Enrolle d Patients
If the sponsor or invest igator ident ify a patientwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue on 
study  treatm ent.  If the invest igator and the sponsor clinical research physician (CRP )agree i t is 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
sponsor CRP to allow the inadvertently enro lled patientto continue in the study  with or wi thout 
treatm ent wi th invest igational product. Safety  follow-up is as outlined in Sect ion 2(Schedule of 
Activities), Section 9.2(Adverse Events), and Sectio n9.4(Safet y) of the protocol.
I8F-MC-GPG H(c) Clinical Protocol Page 49
LY32981768.2. Discontinuation from the Study
In order to minimize the amount of missing data and to enable assessment of study  objectives as 
planned in the study  protocol , every  attem pt will  be m ade to keep pati ents in the study  
irrespect ive of the following:
adherence to study  drug
adherence to visit schedule
missing assessments
study  drug di scont inuat ion due to AE 
development of comorbidit ies, and
development of clinical outcomes .
The ci rcumstances listed above are not valid reasons for disco ntinuat ion from the study . 
Patients will be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or me dically  com patible wit h this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce (GCP)
If a female pat ient beco mes pregnant
If a patient i s diagnosed wi th T1DM
patient requests to be withdrawn from the study
Patients who agree to provide informat ion relevant to any  study endpoint at the end of the study  
are not considered to have discontinued from the study .
A pat ient who withdraws consent and clearly indicates that there will be no further contact of any 
kind with the site will be considered to have discont inued fro m the study .
Prior to early  study  discontinuati on, the pati ent may discont inue study  drug and will have 
end-of-study  procedures (ET visit) performed as shown in the Schedule of Act ivities (Secti on2).  
During the ET visit, the patient will be prescribed an appropri ate gl ucose -lowering regimen and 
glucose self -monitoring plan. Visit 801 ( safety follow
-up visit) shoul d be perform ed 
approximately  4 weeks after the ET visit as the final study  visit.
Patients discont inuing fro m the study  prem aturely for any  reas on shoul d com plete AEand other 
safet y follow
-up per Secti on2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and 
Secti on9.4(Safet y) of this protocol .
8.3. Lost to Follow -up
A pat ient will be considered lost to fo llow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by  the s tudy site.  Every  attem pt will  be made to minimize 
I8F-MC-GPG H(c) Clinical Protocol Page 50
LY3298176the number of patients considered lost to fo llow-up at the end of the study .  Pati ents will be 
inform ed about the importance of complet ing the study  and provi ding updated contact 
inform ation to the study  site when necessary .
I8F-MC-GPG H(c) Clinical Protocol Page 51
LY32981769.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the l aboratory  tests that will be performed for this study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days o f recei pt of  confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Assessments and P rocedures
The primary  efficacy  measurement in this study  is mean change in HbA1c from baseline to 
52weeks, as determined by the central laboratory .  Blood sam ples for HbA1c measurements will 
be co llected at specific clinic visits as summarized in the Stud y Schedule , Secti on 2. 
9.1.2. Secondary Efficacy Assessments and Procedures
The fo llowing secondary  efficacy measures will be assessed at 52 weeks based on data collected 
at the times shown in the Study  Schedule.
Change in HbA1c from baseline
Change in weight from baseline
Proporti on of  patients achieving a target HbA1c <7% (53 mmo l/mol)
Fasting serum glucose measured in the central laboratory 
Change in 7
-point SMBG profiles
Proporti on of  patients who achieved weight loss≥5%, ≥10%, and ≥15% from baseline
oPatient-reported outcomes:
oDiabetes Treatm ent Satisfaction Questionnaire status andDiabetes Treatment 
Satisfact ion Quest ionnaire change
oImpact of Weight on Self -Percept ion
oAbilit y to Perform  Physical Act ivities of Daily  Living
9.1.3. Exploratory Efficacy Assessments and Procedures
The fo llowing secondary  efficacy measures will be calculated based on data collected at the 
times shown in the Study  Schedule.
Chang ein lipids (total cho lesterol , high -densi ty lipoprotein ( HDL ),very low-densit y 
lipoprotein (VLDL ), and triglyceri des)
Change in waist circumference
Biomarkers
European Qualit y of Life dimensio ns (EQ -5D- 5L)scores
I 8 F -M C -G P G H( c) Cli ni c al Pr ot o c ol P a g e 5 2 
L Y 3 2 9 8 1 7 6 9. 1. 4. A p pr o pri at e n e s s of A s s e s s m e nt s 
Efficac y a n d safet y assess me nts i ncl u de d i n t his st u d y  are ge nerall y  re gar de d as relia ble a n d 
acc urate wit h res pect t o t he efficac y a n d safet y assess me nts i n i n di vi d uals a n d p o p ulat i o ns wit h 
T 2 D M. 
9. 2. A d v er s e E v e nt s 
I n vest i gat ors are res p o nsi ble f or m o nit ori n g t he safet y of pat ie nt sw h o ha ve e ntere d t his st u d y  
a n d f or al erti n g Lill y  or i ts desi g nee t o a n y  e ve nt t hat see ms u n us ual, e ve n if t his e ve nt ma y be 
c o nsi dere d a n u na nt ic i pate d be nefit t o t he pati e nt .
T he i n vest i gat or is res p o nsi ble f or t he a p pr o priate me dical care of pat ie nt sd uri n g t he st u d y. 
I n vest i gat ors m ust d oc u me nt t h ei r re vie w of eac h la b orat or y  safet y  re p ort. 
T he i n vest i gat or re mai ns res p o nsi ble f or f o ll o wi n g, t hr o u g h a n a p pr o priate healt h care o pti o n, 
A Es t hat are seri o us or ot her wise me dicall y i m p orta nt, c o nsi dere d relate d t o t he i n vest i gat i o nal 
pr o d uct or t he st u d y, or t hat ca use d t he pati e nt t o disc o nti n ue t he i n vest i gat i o nal pr o d uct bef ore 
c o m plet i n g t he st u d y.  T he pati e nt s h o ul d b e f ol l o we d u nt il t he e ve nt res ol ves or st a bilizes wit h 
a p pr o priate dia g n ostic e val uati o n . For e ve nts t hat are n ot a ntici pate d t o res ol ve or sta bilize, t he 
pati e nt s h o ul d b e f ol l o we d u nt il t he treati n g p h ysicia n (i n c o ns ultat i o n wi t h  t he s p o ns or) 
deter mi nes t hat a p pr o priate f o ll o w- u p has bee n c o m plete d. T he fre q ue nc y o f f o ll o w- u p 
e val uat i o ns of t he A E is left t o t he d iscret i o n of t he i n vest i gat or. 
Lac k of dr u g effect is n ot a n A E i n cli nical st u dies, beca use t he p ur p ose of t he cli nical st u d y is t o 
esta blis h treat me nt effect. 
After t he I C F is si g ne d, st u d y  si te pers o n nel will rec or d via t h e e C R F ,t h e occ urre nce a n d nat u re 
of  eac h pati e nt ’s pree xist i n g c o n dit i o ns, i ncl u di n g cli nicall y si g nifica nt si g ns a n d s y m pt o ms of 
t h e disease u n der treat me nt i n t he st u d y .  I n a d dit i o n, si te pers o n nel will rec or d a n y  c ha n ge i n t he 
c o n di ti o n(s) a n d a n y  ne w c o n di ti o ns as A Es . F or eac h AE, t he o nset a n d d urati o n, t he 
seri o us ness a n d se verit y,  a n d t he act i o ns ta ke n wit h res pect t o st u d y treat me nt will be rec or de d. 
I n vest i gat ors s h o ul d rec or d t heir assess me nt of t he p ote ntial relate d ness of eac h A E t o pr ot oc ol 
pr oce d ure, i n vest i gat i o nal pr o d uct, vi aelectr o ni ccase re p ort f or m ( eC R F ). 
Pr oce d ures a n d assess me nts perf or me d pri or t o Visit 3 are c o nsi dere d scree ni n g pr oce d ures. T he 
res ul ts of  t hese pr oce d ures a n d assess me nts s h o ul d be c o nsi dere d pre -e xist i n g c o n dit i o ns a n d 
s h o ul d be re p orte d as me dical hist or y or c o nc o mita nt ill ness.   
T he i n vest i gat or will i nter pret a n d d oc u me nt w het her or n ot a n A E has a reas o na ble p ossi bilit y 
of  bei n g relate d t o st u d y  treat m e nt, st u d y  de vice, or a st u d y  pr oce d ure, ta ki n g i nt o acc o u nt t he 
di sease, c o nc o mita nt  treat m e nt or pat h ol o gies. 
A “reas o na ble p ossi bilit y” mea ns t hat t here is a ca use a n d effect relat i o ns hi p bet wee n t he 
i n vesti gat i o nal pr o d uct, st u d y  de vice a n d/ or st u d y  pr oce d ure a n d t he A E. 
T he i n vest i gat or a ns wers yes/ n o w he n ma ki n g t his assess me nt. 
I8F-MC-GPG H(c) Clinical Protocol Page 53
LY3298176Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational product is discontinued as a result of an AE, study site perso nnel 
must report this to Lilly or its designee via the CRF , clarifying if possible, the circumstances 
leading to any  dosagemodifications, or discontinuations o f treatm ent.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the following outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospitali zation but m ay jeopardi ze the patient or m ay require intervent ion 
to prevent one of the other outcomes listed in the definit ion above.   Examples of 
such m edical events include allergic bronchospasm requiring intensive treatment 
in an em ergency room  or at hom e, blood dy scrasias or convulsions that do not 
resul t in inpat ient hospi talizat ion, or the development of drug dependency  or drug 
abuse.
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patienthas signed the ICF and has 
received invest igational product.  However, if an SAE occurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
reporting requirements and t imelines (see Sect ion 9.2) if it is considered reasonably possibly  
related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.   If alerts are issued via telephone, they  
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.Patients with a seri ous hepat ic AEshoul d have addi tional data collected using th e 
eCRF .(see Section 9.4.5.1 )
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they  have 
discontinued and/or completed the study  (the patientdisposit ion eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
I8F-MC-GPG H(c) Clinical Protocol Page 54
LY3298176been discharged from the study , and he or she considers the event reasonably possibly related to 
the study  treatm ent or study  parti cipati on, the investi gator m ust prom ptly notify Lilly.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated de tailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of SUSARs. Lilly has procedures that will be fo llowed for the 
ident ificat ion,recording ,and expedited reporting of SUSARs that are consistent with globa l 
regul ations and the associated detailed guidances.
9.2.2. Adverse Events of Special Interest
9.2.2.1. Hypoglycemia 
Patients will  collect inform ation on epi sodes of hypoglycemia starting from Visit 2 until the last 
study  visit (Foll ow-up Vi sit or Early Terminat ion Visit).  For that purpose, patients will be 
trained about signs and symptoms o f hypoglycemia, how to treat hy poglycemia, and how to 
collect appropriate informat ion for each episode of hy poglycemia in the study  according to the 
Schedule of Act ivities.  Site pers onnel will enter this informat ion into the eCRF at each visit. 
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an episode considered to be related to hy poglycemia  (the plasma glucose [PG]values in this 
section refer to values determined by a laboratory  or Internati onal Federat ion of Clinical 
Chemistry  and Laboratory  Medicine plasma -equival ent gl ucose m eters and strips) (ADA 2017):
Glucose Alert Value (Le vel 1):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels 
thatheor sheis experiencing symptoms and/or signs associated with 
hypoglycemia, and has a PG l evel of ≤70 mg/dL (≤3.9 mmo l/L).
Documented asymptomatic hypoglycemia is def ined as any  event not 
accompanied by typical symptoms of hypoglycemia, but with a measured PG 
≤70mg/dL (≤3.9 mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no 
inform ationabout sym ptoms of hypoglycemia available, but with a measured PG 
≤70 m g/dL (≤3.9 mmo l/L).
Clinically Significant Hypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels 
thathe/she is experiencing symptoms and/or signs associ ated wi th hypoglycemia, 
and has a PG l evel of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by typical symptoms of hypoglycemia, but with a measured PG <54 
mg/dL (<3.0 mm ol/L).
I8F-MC-GPG H(c) Clinical Protocol Page 55
LY3298176Documented unspecified hypoglycemia is defined as any  event wi th no 
inform ationabout sym ptoms of hypoglycemia available, but with a measured PG 
<54 m g/dL (<3.0 mmo l/L).
Severe hypoglycemia (Level 3):
Severe hypoglycemia is defined as an episode with severe cognit iveimpairment 
requi ring the assistance of another person to actively  administer carbohydrate, 
glucagon, or other resuscitative act ions.  These episodes may  be associ ated wi th 
sufficient neuroglycopenia to induce seizure or coma. Blood gl ucose 
measurements m ay not be available during such an event, but neurological 
recovery  attributable to the restoration of BG to normal is considered sufficient 
evidence that the event was induced by a low BG concentration.
Other hypoglycemia categories:
Nocturnal hypoglycem iais defined as any hypoglycemic event that occurs 
between bedtime and waking.
If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious on the AE 
CRF and reported to Lilly as an SAE.
To avoid duplicate reporting, all consec utive BG values ≤70 mg/dL (3.9 mmo l/L) occurring 
within a 1- hour period may be considered to be a single hypoglycemic event (Weinberg etal.
2010; Danne et al. 2013).  
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly  
categori zed, the effect of the intervention be assessed, and the frequency of hypoglycemia be 
evaluated.  The role of dietary  changes and physical  exercise (or any  other contribut ing factor) in 
the development of an event should be established.  T he patient should receive addit ional 
education, if deemed appropriate.  The dose of concomitant antihyperglycemic medicat ions may 
need to be reduced as outlined in Secti on 7.4.2 .
9.2.2.2. Severe, Persistent Hyperglycemia
Severe, persistent hy perglycemia will be collected during the trial to assess the risk of extreme 
imbalance in glycemic control.
Invest igators will be traine d on the applicat ion of cri teria for deci ding when and how to intervene 
with patients who do not reach glycemic targets.  An addit ional therapeut ic intervent ion shoul d 
be considered in pat ients who develop severe, persistent hyperglycemia after randomizat ion at 
the discret ion of invest igator in accordance with American Diabetes Associat ion/European 
Associ ation for the Study  of Diabetes guidance (Inzucchi et al . 2015 ).  Rescue medicat ion will 
be prescribed as add -on to randomized treatment, and patients will continue to follow the 
protocol -specified visit schedule.
Add-on glycemic rescue therapy  will be allo wed for pati ents who m et any  one of the following 
prespecified criteria for severe, persistent hy perglycemia and no intercurrent cause of the 
hyperglycemi a coul d be ident ified (invest igators should first confirm that the patient is fully 
I8F-MC-GPG H(c) Clinical Protocol Page 56
LY3298176compliant wi th the assigned therapeutic regimen and that he or she does not have an acute 
condi tion causing severe hyperglycemia): 
(a)average daily  BG f rom the once -weekly  4-point SMBG profile >270 mg/dL 
(>15.0 mmo l/L) over at l east a consecut ive 2 -week period any t ime during the first 8 
weeks post randomizat ion; 
OR 
(b)average daily  BG f rom the once -weekly  4-point SMBG profile >240 mg/dL 
(>13.3 mmo l/L) over a consecut ive 2 -week period at any  time 9 to 16 weeks post 
rando mizat ion; 
OR
(c)average daily  BG f rom the once -weekly  4-point SMBG profile >200 mg/dL 
(>11.1 mmo l/L) over a consecut ive 2 -week peri od at any  time bey ond the first 16 weeks 
post rando mizat ion.
OR
(d)HbA1c ≥8.5% at 24 weeks, with inadequate response to the existing regimen defined as 
improvement in HbA1c over the last 3 months (week 12 to week 24) that is <0.3%
Rescue therapy  option:
For the insulin degludec group , pati ents can further titrate the insulin degludec .  Thecriteria 
described above for severe, persi stent hy perglycemia will only  be applicable after Week 16.  The 
first choi ce before init iating any rescue therapy for those patients during the init ial 16 weeks will 
be to fo llow the TTT al gorithm to increase the dose of insulin degludec. 
Rescue treatment with pramlint ide, DPP- 4 inhibitors, or GLP -1 receptor agonists will not be 
allowed.  Addit ionally, use of other basal insulins will not be allowed in the insulin degludec
group .
9.2.2.3. Pancreatitis
Acute pancreat itis is defined as an AE of interest in all trials with LY3298176 including this 
trial.  Acute pancreat itis is an acute inflammatory  process of the pancreas that may also involve 
peripancreat ic tissues and/or remote organ sy stem s (Banks and Freeman 2006).  The diagnosis of 
acute pancreatit is requires 2 of the fo llowing 3 features:
abdo minal pain, characterist ic of acute pancreat itis (generally located in the 
epigastri um and radi ates to the back in approximately half the cases [Ba nks and 
Freeman 2006; Ko izumi et al . 2006]; the pain is often associated with nausea and 
vomiting);
serum  amylase (total and/or pancreatic) and/or lipase ≥3XULN
characterist ic findings of acute pancreat itis on computed tomography  (CT) scan or 
magnet ic resonance imaging (MRI).
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lipase) should be obtained via the central laboratory  (and l ocally, if needed).  
I8F-MC-GPG H(c) Clinical Protocol Page 57
LY3298176Imaging studies, such as abdo minal CT sca n with or wi thout con trast, MRI, or gallbladder 
ultrasound, should be performed.  If laboratory  values and/or abdominal imaging support the 
diagnosis of acute pancreat itis, the patient must discontinue therapy wit h invest igational 
product(s) ,but will cont inue in the study  on another gl ucose -lowering regimen (details on rescue 
intervent ion will be provided).  The most appropriate diabetes therapeutic regimen will be 
decided by  the investi gator, based on the patient’s clinical status.  A review of the patien t’s 
concomitant medicat ions should be conducted to assess any  potenti al causal  relati onship wi th 
pancreat itis.
Each case o f AE of pancreat itis must be reported.  If t ypical signs and/or symptoms o f 
pancreat itis are present and confirmed by laboratory value s (lipase or amylase [total and/or 
pancreat ic]) and imaging studies, the event must be reported as an SAE.  For a potential case that 
does not m eet all of these criteria, it is up to the investigator to determine the seriousness of the 
case (AE or SAE) and the relatedness of the event to study  drug(s).
Each patient will have measurements of p -amylase and lipase (assessed at the central laboratory) 
as shown on the Schedule o f Activities (Secti on2)to assess the effects of the investigational 
doses of LY3298176 on pancreat ic enzyme levels. Serial measures of pancreatic enzymes have 
limited clinical value for predict ing episodes of acute pancreatit is inasymptom atic pat ients 
(Nauck et al. 2017; Steinberg et al. 2017a; Steinberg et al. 2017b). Thus, further diagnost ic 
follow
-up of  cases of asymptomat ic pancreat ic hyperenzymemia (lipase and/or pancreatic 
amylase ≥3XULN) is not mandated but may  be perform ed based on the invest igator’s clinical 
judgment and assessment of the patient’s overall clinical condit ion.Only cases of pancreat ic 
hyperenzymemia that undergo additional diagnostic fo llow-up and/or are accom panied by 
symptoms suggest ive of pancreat itiswill be submitted for adjudication.
All suspected cases of acute or chronic pancreat itis will be adjudicated by  an independent 
clinical endpo int committee (CEC). In addit ion, AEs of severe or serious abdo minal pain o f 
unknown et iology will also be submi tted to the adjudi cation commit tee to assess for possible 
pancreat itis or other pancreatic disease. Relevant data from patients with acute or chronic 
pancreat itis and those with severe or serious abdominal pain will be entered into a specifically 
designed eCRF page by study  site or Lilly  staff .The adjudicat ion committee representative will 
enter the results of adjudicat ion in a corresponding eCRF page.
9.2.2.4. Thyroid Malignancies and C -Cell Hyperplasia
Individuals with personal or family history  of MTC and /ormultiple endocrine ne oplasia t ype 2 
(MEN-2) will be excluded fro m the study .  The assessment of thyroid safet y during the study
will include reporting of any case of  thyroid malignancy including MTC and papillary  carcino ma
and measurements of calcit onin.  This data will be captured in specific eCRFs. The purpose of 
calcitonin measurements i s to assess the potential of LY3298176 to affect thy roid C-cell 
funct ion, which may indicate development of C -cell hyperplasia and neopl asms .  LY3298176
shoul d be discont inued (after first confirming the value) if postrandomizat ion calcitonin value is 
≥35 ng/Landhas increased at least 50% over baseline.  A consultat ion with a thy roid specialist 
(if not available, an endocrino logist) shoul d be obtained.
I8F-MC-GPG H(c) Clinical Protocol Page 58
LY3298176If the increased calcitonin value ( ≥35 ng/L and increases by  ≥50% com pared withbaseline) is 
observed in a patient who has administered a medication that is kno wn to increase serum 
calcitonin, this medicat ion shoul d be stopped and calcito nin levels shoul d be m easured after an 
appropriate wash out period.  If the confirmed calcitonin value is <35 ng/L, LY3298176 shoul d 
be restarted when it is safe to do so.  
9.2.2.5. Major Adverse Cardiovascular Events
Deaths and nonfatal cardi ovascular (CV)AEs will be adjudicated by a co mmittee of physicians 
external to Lilly with cardio logy experti se.  The nonfatal C V AEs to be adjudicated include the 
following :  
myocardial  infarct ion
hospi talizati on for unstable angina
hospitalizati on for heart failure
coronary  intervent ions (such as coronary  artery  bypass graft or percutan eous coronary  
intervent ion)
cerebrovascular events, including cerebrovascular accident (stroke ) and transient 
ischemic attack
9.2.2.6. Supraventricular Arrhythmias andCardiac Conduction Disorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Patients who 
develop any event from this group of di sorders shoul d undergo an ECG which should be 
submitted to the central reading center. Addit ional diagnostic test s todetermine exact diagnosis 
shoul d be perform ed, as needed. The specific diagnosis will be recorded as an AE. Events that 
meet criteria for serious conditions as described in Section 9.2.1 must be reported as SAEs .
9.2.2.7. Hypersensitivity Events
All allergic or hy persensi tivity react ions will be reported by the invest igator as either AEs or, if 
any serious criterion is met, as SAEs.  Addit ional data, such as type of reaction and treatment 
received, will be collected on any AEs or SAEs that the investigator deems related to study 
drug(s) vi a a CRF created for this purpose. Addit ional samples should also be co llected a s 
outlined in Sect ion 9.4.3 .  Study  drug(s) shoul d be tem porarily interrupted in any individual 
suspected of having a severe or serious allergic re action to study  drug(s).  Study  drug(s) m ay be 
restarted when/if it is safe to do so, in the opinio n of the invest igator.  If study drug(s) is 
perm anent ly discont inued, the patient will receive another glucose -lowering treatm ent, j udged by 
the invest igator to be appropriate based on the patient’s clinical status, and will cont inue in the 
trial to collect all plan ned ef ficacy and safet y measurem ents. 
9.2.2.7.1. Injection Site Reactions
Inject ion site reactions will be co llected on the eCRF separate from the hypersensi tivity react ion 
eCRF.  At the time of AE occurrence in the LY3298176 group , samples will be collected for 
measurement of LY3298176 ADA and LY3298176 concentration.
9.2.2.7.2. Anti-Drug Antibodies
The occurrence of ADA format ion will be assessed as outlined in Section 9.4.3 . 
I8F-MC-GPG H(c) Clinical Protocol Page 59
LY32981769.2.2.8. Diabetic Retinopathy Complications
Dilated retinal fundoscopi cexaminat ion will be performed by  a qualified eye care professio nal 
(ophthalmo logist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients 
with proliferat ive ret inopathy  and/or m aculopathy .  The resul ts from this examinat ion will be 
recorded on a specific retinopathy  eCRF as a baseline measure of retinopathy .  
A follow-up dilated fundoscopi cexaminat ion should be perfo rmed when clinically  indicated by 
any AEsuspected of worsening retinopathy ,and the findings shoul d be recorded on the 
retino pathy  eCRF.  
9.2.2.9. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecyst itis, or oth er suspected events related to gallbladder 
disease shoul d be evaluated and addit ional diagnostic tests performed, as needed. In cases of 
elevated liver m arkers, hep atic monitoring shoul d be init iated as outlined in Sect ion 9.4.5.1 and 
Appendix 4 .
9.2.2.10. Severe Gastrointestinal Adverse Events
LY3298176 may cause severe GI AEs, such as nausea, vo miting, and diarrhea.  Informat ion 
about severe GI AEs as well as antiemetic/antidiarrheal use wil l be co llected in the eCRF/AE 
form.  For detailed information concerning the management of GI AEs, please refer to 
Secti on7.7.1 .
9.2.2.11. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ional assessment as well as 
assessment of AEs suggest ive o f acute or worsening of chronic renal failure .  Gastrointestinal
AEs have been reported with LY3298176, including nausea, diarrhea, and vo miting. These are
consistent with other GLP -1 receptor agonists (Aroda and Ratner 2011). The events may lead to 
dehydrat ion, which could cause a deterioration in renal function, in cluding acute renal failure. 
Patients shoul d be advised to notify investigators in case of severe nausea, frequent vomit ing, or 
symptoms of dehydrat ion.
9.2.2.12. Metabolic Acidosis , Including Diabetic Ketoacidosis
Ketoacidosis, a serious life -threatening condition requiring urgent hospitalization, has been reported 
rarely in patients with T2DM.  Patients who present with signs and symptoms consistent with severe 
metabolic acidosis should be assessed for ketoacidosis regardless of presenting BGlevels, as 
ketoacidosis may be present even if BGlevels are less than 250 mg/dL. If ketoacidosis is suspected, 
SGLT -2i should be discontinued (if used), patient should be evaluated, and prompt treatment should 
be instituted.  Treatment of ketoacidosis ma y require insulin, fluid and carbohydrate replacement.
Lactic acidosis has been reported rarely in patients with T2DM associated with use of metformin, 
excessive alcohol intake and decrease renal function.  Routine bicarbonate assessment will be 
performed during the course of the study.  If lactic acidosis is suspected, metformin should be 
temporarily discontinued until the resolution of the event.
9.2.2.13. Amputation/Peripheral Revascularization
All cases of amputation and peripheral revascularization should be reported as an AE.
I8F-MC-GPG H(c) Clinical Protocol Page 60
LY32981769.2.2.14. Major Depressive Disorder/Suicidal Ideation 
The prevalence of depressive symptoms and disorders is increased in patients with T1DM or T2DM 
(ADA Guideline, 2017). Any AEof major depressive disorder or suicidal ideation should be 
reported.
9.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate pr ocess and product improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em w ith the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
Study  drug overdose (more than the specified n umber of injections) will be reported as an AE.  
In the event of overdose, refer to the IB for LY3298176 and/or Product Label for insulin 
degludec (Degludec USPI, 2015 [WWW] ).
9.4. Safety
9.4.1. Electrocardiograms
For each patient, electrocardi ogram s(ECGs) should be collected according to the Schedule of 
Activities (Secti on 2).  Electrocardi ograms shoul d be recorded according to the study -specific 
recommendat ions includ ed in the Man ual of Operati ons for the study .  
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and i deally  
while the patient is still present, for immediate subject management, should any clinically 
relevant findings be identified .  
Any clinically significant findings fro m ECGs that result in a 
diagnosis and that occur after the pati ent receives the firs t dose of the invest igational treatment 
shoul d be reported to Lilly or its designee as an AE via the eCRF.
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory .The central ECG laboratory  
will perform a basic qualit y control  check ( for example , dem ographics and study  details) and 
then store the ECGs in a database. At a future time, the stored ECG data may be overread by a 
cardi ologist at the central  ECG l abora tory for further evaluat ion of machine -read measurements 
or to m eet regul atory  requi rements. The m achine -read ECG intervals and heart rate may be used 
for data analysis and report -writing purposes, unless a cardio logist overreading of the ECGs is 
conducte d prior to com pletion of the final study  report (in which case, the overread data would 
be used).
9.4.2. Vital Signs
For each patient, vitalsigns measurements should be conducted according to the Schedule o f 
Activities (Secti on 2) and fo llowing the study -speci fic reco mmendat ions included in.  
I8F-MC-GPG H(c) Clinical Protocol Page 61
LY3298176Any clinically  significant findings from vital signs measurement that result in a diagn osis and 
that occur after the patientreceives the first dose of study treatment should be reported to Lilly or 
its designee as an AE via eCRF.
9.4.3. Laboratory Tests
For each patient,laboratory  tests detailed in ( Appendix 2 ) shoul d be conducted according to the 
Schedule of Act ivities (Secti on 2). 
With the exception o f laboratory  test resul ts that may  unblind the study (if applicable) , Lilly or 
its designee will provide the investigator with the results of laboratory  tests analyzed by  a central
vendor, if a central vendor is used for the clinical trial.  
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the patientreceives the first dose of invest igatio nal product should be reported to Lilly or its 
designee a s an AE via eCRF.
9.4.4. Immunogenicity Assessments 
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to determine ant ibody  producti on against LY3298176 as specified in the Schedule of 
Activities (Section 2).
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2), venous blood samples 
will be co llected to determine ant ibody  producti on against the LY3298176 .  To interpret the 
resul ts of immunogenicit y, a PKsample will  be collected at the same time po intsas the 
immunogenicit y sample .  
All samples for immunogenicit y shoul d be taken predose when 
applicable and possible.  In the event of drug hypersensit ivity react ions (immediate or 
non-immediate), addit ional samples will be collected (including ADA, PK ,and exploratory  
immune safet y sample) as close to the onset of the event as possible, at the resolut ion of the 
event, and 30 day s following the onset of the event.  Instructions for the collect ion and handling 
of blood sam ples will  be provi ded by the spon sor.  Sample collected at Visit 801 will assess 
immunogenicit y at washout of LY3298176 (5 half -lives post end of treatment).
Treatment -emergent ADAs are defined in Sect ion10.3.5 .
Samples wi th LY3298176 ADA detected will be titered and evaluated for their abilit y to 
neutralize the activit y of assigned treatment ( LY3298176 -neutralizing ant ibodies).  Samples with 
LY3298 176ADA detected will also be tested for cross -reactive binding to native GIP and 
GLP -1, and, if such is detected, then for neutralizing antibodies against nat ive GIP and GLP -1, 
respectively .
Samples will  be retained for a m aximum  of 15 y ears after the l ast patient visit, or for a shorter 
period if local  regulat ions and ethical review boards (ERBs) allow, at a facilit y selected by  the
sponsor.  The duration allows the sponsor to respond to future regulatory  requests rel ated to 
LY3298176 .  Any samples remaining after 15 y ears will  be destroy ed.
I8F-MC-GPG H(c) Clinical Protocol Page 62
LY32981769.4.5. Safety Monitoring 
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods.
9.4.5.1. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X U LN, or el evated TBL 
≥2X ULN, liver testing ( Appendix 4 ) shoul d be repeated wi thin 3 to5 day s including ALT, AST, 
ALP, TBL, direct bilirubin , gamma- glutamyl  transferase, and creat ine kinase to confirm  the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultation with the study  medical mo nitor.Monitoring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels . 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1 or more of the following condi tions 
occur: 
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated serum TBL to ≥ 2X ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALPto ≥2X ULN on 2 or more consecutive blood tests
patientdiscont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
hepatic event considered to be a SAE
9.5. Pharmacokinetics
Not applicable .
9.6. Pharmacodynamics
Not applicable .
9.7. Pharmacogenomics
9.7.1. Whole Blood Sample sfor Pharmacogenetic Research
A whole blood sam ple will  be collected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Secti on2)where local regulat ions allow.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable response to LY3298176 and to 
investigate genet ic variants though t to pl ay a rol e in T2DM .  Assessment of variable response 
may include evaluation o f AEs or differences in efficacy .  
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by  the invest igator site personnel .  
I8F-MC-GPG H(c) Clinical Protocol Page 63
LY3298176Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15years 
after the l astpatient vi sit for the study , or f or a shorter period if local regulations and/ or 
ERBs /invest igational review boards impose shorter time limits.  This retention period enables 
use of new techno logies, response to regulatory  questi ons, and invest igation of variable response 
that may  not be observed unt il later in the devel opment of LY3298176 or after LY3298176
beco me(s) commercially  available .
Molecular techno logies are expected to improve during the 15 -year storage period and therefore ,
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencin g, geno me wide association studies, and candidate gene studies.  Regardless of 
techno logy utilized genoty ping data generated will be used only for the specific research scope 
described in this sect ion. 
9.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical st udies to enable examinat ion of 
these quest ions through measurement of bio molecul es including deoxy ribonucleic acid ( DNA ), 
ribonucleic acid ( RNA ), proteins, lipids, and other cellular elements.
Serum and plasma samples for nonpharmacogenetic biomarker resea rch will be co llected at the 
times specified in the Schedule of Act ivities (Section 2)where local regulat ions allow.
Samples will  be used for rese arch on the drug target, disease process, variable response to 
LY3298176 , 
pathway s associ ated wi th T2DM , mechanism  of action of  LY3298176 , and/or 
research method or in validat ing diagnost ic tools or assay(s) related to T2DM.   
All samples will be coded wit h the patient number.  These samples and any data generated can 
be linked back to the patient only by the invest igator site personnel .  
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  15 years 
after the l ast pati ent visit for the study, or for a shorter period if local regulations and ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observed until later 
inthecourse of the development and commercialization of both study drugs.
9.9. Health Economics
The following quest ionnaires will be completed by the patients at specific clinic visit s according 
to the Schedule of Events (Section 2). At these visits, the questionnaires should be co mpleted 
before the patient has discussed their medical condit ion or progress in the study  with the 
investigato r and/or site staff and before any other study  procedures if the pat ient is not adversely 
affected by  their fast ing condit ion.
I8F-MC-GPG H(c) Clinical Protocol Page 64
LY32981769.9.1. Diabetes Treatment Satisfaction Questionnaire 
The status (s) and change (c) versio ns of the DTSQ will be used during the study  to assess the 
patients’ sat isfaction wit h their diabetes treatment and the perceived frequency o f hyperglycemia 
and hypoglycemia.  The questionnaire contains 8 items (Bradley 1994).  Each item is rated on a 
7-point Likert scale.  Six items (1 and 4 through 8) are summed to produce a measure of 
treatm ent sati sfact ion ranging fro m 0 “very  dissat isfied” to 6 “very sat isfied.
”  The remaining 2 
items (2 and 3) are treated individually.  Item 2 measures the perceived frequency  of 
hyperglycemia on a scale ranging f rom 0 “none of the time” to 6 “most of the time,” and Item 3 
measures the perceived frequency  of hypoglycemia on the same scale.  The change versio n has 
the sam e 8 items as the status version wit h a small alteration of the wording of Item 7.  The 
DTSQ changeresponse options differ fro m those of the DTSQ status to produce measures of 
relative change rather than abso lute sati sfact ion.
9.9.2. Impact of Weight on Self -Perception Questionnaire
The IW -SP questi onnaire contains 3 items that assess how often the patients’ body  weight affects 
how happy  they are wi th their appearance and how often they  feel self -conscious when out in 
public (Hayes and DeLozier 2015).  Each item is rated on a 5 -point scale ranging fro m “always” 
to “never.”  Total scores for the IW -SPare derived by summing the item scores and dividing by 
the number of items.  The score can also be transformed to a range fro m 0to100.  Higher IW -SP 
scores correspond to better self -percept ion (Hay es and DeLozi er 2015).
9.9.3. Ability to Perform Physical Activ ities of Daily Living
The APPADL quest ionnaire contains 7 items that assess how difficult it is for patients to engage 
in certain act ivities considered to be integral to normal daily life, such as walking, standing ,and 
climbing stairs (Hay es et al . 2011; Hayes et al. 2012).  Items are scored on a 5- point numeric 
rating scale, where 5 =“not at all difficult” and 1 =“unable to do.”  A raw overall score is 
calculated by simply  summing the scores of the 7 items, and a transformed overall score is 
obtained b y linearly  transforming the raw overall score to a 0 to 100 scale.  A higher raw overall 
score and a higher transformed overall score are indicat ive of better abilit y to perf orm activit ies 
of daily living.  
9.9.4. European Quality of Life 
Generic health-related qualit y of lifewill be assessed using the EQ -5D- 5L (EuroQoL Group 
2015).  The EQ -5D- 5L is a standardized 5-item instrum ent for use as a m easure of healt h 
outcom e.  It provi des a simple descript
ive profile and a single index value for health status that 
can be used in the clinical and econo mic evaluat ion of healt hcare as well as populat ion health 
surveys.  The EQ-5D- 5L com prises 5 dimensio ns of health (mobilit y, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depressi on).  The 5L versio n, introd uced in 2005, scores each 
dimensio n at 5 l evels (no probl ems, slight problems, moderate problems, severe problems, 
unable to perform/extreme problems), for a total of 3251 possible health states.  In addit ion to the 
healt h profile, a single healt h state in dex value can be derived based on a formula that attaches 
weights to each of the levels in each dimensio n. This index value ranges between l ess than 0 
I8F-MC-GPG H(c) Clinical Protocol Page 65
LY3298176(where 0is a health state equivalent to death; negative values are valued as worse than dead) to 1 
(perfect health).   In addit ion, the EQ Visual Analo g Scal erecords the respondent ’s self -rated 
healt h status on a vertical graduated (0 to 100) visual analogscale.   In conjunct ion with the 
healt h state data ,it provi des a co mposite picture of the respondent’s healt h status.  
The EQ -5D- 5L is used worldwide and is available in more than 170 different languages.  Details 
on the instrument, and scoring, organizing, and presenting the data collected can be found in the 
EQ-5D- 5L User Guide (EuroQoL Group 2015). 
I8F-MC-GPG H(c) Clinical Protocol Page 66
LY329817610.Statistical Considerations
10.1. Sample Size Determination
Patients will  be randomized in a 1:1:1:1 ratio to LY3298176 5 mg, 10 mg, 15 m g, orinsulin
degludec.  Although the primary object ive of the trial is to demonstrate that once -weekly 10 mg 
and/or 15 m g doses are noninferior to titrated insulin degludec relat ive to mean change in HbA1c 
from baseline (using a 0.3% noninferiorit y boundary ), the study  is powered to assess superiorit y 
of LY329817 610 m g and 15 m g,each tested in parallel against titrated insulin degludec at a 
2-sided significance level o f 0.025, rel ative to the primary endpo int (mean change in HbA1c 
from baseline to 52 weeks), under the fo llowing assum ptions:  use of a 2- sample t-test utilizing 
HbA1c data collected before init iation of any rescue medicat ion or premature treatment 
discontinuat ion with no m ore than 28% of subjects init iating any rescue medication or 
prem aturely  discontinuing treatmen t in each treatment group ; 0.35% greater mean reduction in 
HbA1c fro m baseline for 10 and 15 mg LY3298176 compared with insulin degludec; 1:1:1:1 
rando mizat ion
,a common standard deviat ion (SD) of 1.1% , and a superiorit y boundary of 
0.05% .  On the basis o fthese assumptions, a sample size o f 1420 subjects is required to ensure at 
least 90% power to demonstrate that LY3298176 10mg and/or 15 mg are superior to insulin 
degludec relat ive to the primary endpo int.  Furthermore, this sample size will ensure 90% p ower 
for the superi ority evaluat ion conducted using an analysis o f covariance (ANCOVA) utilizing all 
available HbA1c data at 52 weeks with missing data imputed with a conservative mult iple 
imputati on m ethod (as described in the Efficacy  Analysis sect ion below), provi ded a 0.35% 
greater mean reduction in HbA1c fro m baseline for 10 and 15 mg LY3298176 compared with 
insulin degludec and SD increases to no more than 1.3% due to the inclusio n of data on rescue 
medicat ions and after premature treatment discontinu ation, and imputation of missing data.
10.2. Populations for Analyses
For purposes of analysis, the following analysis sets are defined in Table GPGH. 6:
Table GPGH. 6
. Description of Analysis Sets
Analysis Set Description
Screened patients All participants who sign informed consent
Randomized patients All patients who are r andomly  assigned a treatment group
modified intention -to-treat 
(mITT) setAll randomly assigned participants who are exposed to at least 1 dose of study 
drug.   In the event of a treatment error, participants will be analyzed according 
tothe treatment they were randomized.
Efficacy analysis set (EAS) Data obtained during Study Period II from the mITT set, excluding data after 
initiating rescue antihyperglycemic medication or stopping study drug.
Full analysis set (FAS) Data obtained dur ing Study Period II from the mITT set, regardless of 
adherence to study drug or initiation of rescue antihyperglycemic medication
Safety analy sis set (SAS) Data obtained during Study Periods II or III from the mITT set, regardless of 
adherence to study drug o r initiation of rescue antihyperglycemic medication.
I8F-MC-GPG H(c) Clinical Protocol Page 67
LY329817610.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee.   Any change to 
the data analysis methods described i n the protocol  will require an amendment ONLY if it 
changes a principal feature of the protocol.  Any  other change to the data analysis methods 
described in the protocol, and the just ificat ion for making the change, will be described in the
statist ical analysis plan (SAP) or the clinical study  report (CSR) .  Addit ional exploratory  
analyses o f the data maybe conducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05, and the con fidence interval (CI) will be calculated at 95%, 2 -sided.  In statist ical 
summaries and analyses, patients will be analyzed as rando mized.
There will be 2 estimands o f interest in comparing efficacy o f LY3298176 doses wi th insulin 
degludec.  Fi rst estimand , the “efficacy” estimand, represents efficacy  prior to di scontinuati on of 
study drug wi thout confounding effects of ant ihyperglycemic rescue therapy.  Second estimand, 
the “treatm ent-regimen” est imand, represents the efficacy irrespect ive o f adherence to study drug 
or init iation of rescue antidiabetic drugs.
The primary  efficacy  assessment, gui ded by the “efficacy” est imand, will be conducted using the 
efficacy  analysis set ( EAS ).  The primary efficacy assessment, guided by  the 
“treatm ent-regimen” est imand , will be conducted using the full analysis set ( FAS).  As they  are 
intended for different purposes, no mult iplicit y adjustm ents will be m ade for conducting 2 
primary  efficacy  assessments.
Unless specified otherwise, safet y assessments will be guided by  anestimand co mpar ing safety  
of LY3298176 doses wi th insulin degludec irrespective of adherence to study  drug or init iation 
of antihyperglycemic rescue therapy.  Thus, safet y analysis will be conducted using the SAS.  
Selected safet y analyses will be conduct ed after excluding data on rescue therapy .
Summary  statistics for continuous m easures will  include sam ple size, mean, SD, median, 
minimum, and maximum.  The analysis model to make co mpar isons amo ng treatment groups
relative to continuous measurements asses sed over time will be a mixed model for repeated 
measures (MMRM), with terms :  treatm ent, visit, and treatment -by-visit interaction, country , 
SGLT -2 use (Yes or No), and baseline measurement as a covariate.  An unstructured covariance 
structure will model the relati onship of wi thin-patient errors.
The Kaplan -Meier m ethod will be used for estimatio n of cumulative event -free survival rates 
over time, and cox proportional hazards regressio n analysis will be used to compare hazard rates 
among treatm ents.
Summar y statistics for categorical measures (including categorized continuous measures) will 
include sample size, frequency, and percentages.  Fisher’s exact test will be used to examine the 
treatm ent difference in categorical outcomes.  Logistic regressi on may  be used to examine the 
treatm ent difference in binary  efficacy  outcomes.  Summary  statistics for discrete coun t 
I8F-MC-GPG H(c) Clinical Protocol Page 68
LY3298176measures will include sample size, mean, SD, median, minimum ,and m aximum .  The negat ive 
binomial regressio n model will be used for the treatm ent com parison of discrete count measures.
Other stati stical methods may be used, as appropriate, and details will be documented in the 
SAP.
10.3.2. Treatment Group Comparability
10.3.2.1. Patient Disposition
Frequency counts and percentages of all pat ients screened, rando mized, and receiving at least 1 
dose of study  drug will be presented by  treatm ent groups.  A list ing of rando mized patients not 
receiving study  drug will be provided.  Of the patients in the mITTset, frequency, counts and 
percentages of pat ients com pleting t he study , prematurely  discontinuing the study , including the 
reason for premature discont inuat ion, will be presented by  treatm ent groups.  A Kaplan -Meier 
analysis of time fro m randomization to premature discontinuat ion from study  by treatm ent group 
will be provi ded.
10.3.2.2. Patient Characteristics
Dem ographics, medical history , and conco mitant illness will be summarized by treatment group 
using the mITT set.
10.3.2.3. Concomitant Therapy 
Concomitant medicat ions, including previous therapy  for diabetes, will be summarized by  
anatomical therapeut ic chemical classificat ion and treatment group using the mITT set.  In 
particular, the incidence of init iation of rescue therapy  for severe, persist ent hy perglycemia will 
be analyzed as an exploratory  safet y endpoint.  Dose modificat ions of oral ant ihyperglycemic 
therapy  will also be compared between treatment groups .
10.3.2.4. Treatment Compliance 
Of the pati ents in the m ITT set, frequency counts and percenta ges of patients prematurely  
discontinuing study  drug, including reason for premature discont inuat ion, will be presented by 
treatm ent group.  A Kaplan -Meier analysis o f time fro m rando mizat ion to prem ature study  drug 
discontinuat ionby treatment group will be provided. Treatment compliance for each visit 
interval  is defined as taking at least 75% of required injections of study  drugs.  Frequency  counts 
and percentages of patients compliant to study  drug will be summarized by treatment arms using 
the mITT se t.
10.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
As indicated in Section 10.3.1 , there will be 2 primary  efficacy analyses conducted to establish 
noninferiorit y of LY3298176 10 m g and LY3298176 15 m g to insulin degludec relat ive to mean 
change in HbA1c from baseline to the 52 -week visit.
For the FDA, the primary  efficacy  analysis will  be gui ded by  the “treatm ent-regimen” est imand 
defined in Sect ion 10.3.1 .  This assessment will analyze change in HbA1c values obtained at the 
I8F-MC-GPG H(c) Clinical Protocol Page 69
LY329817652-week visit using ANCOVA with terms, treatment, country ,baseline conco mitant oral  
antidiabet ic treatment (metformin alo ne, m etformin plus an SGLT -2i), and baseline HbA1c as a 
covari ate.  Mi ssing change in HbA1c from baseline values at the 52 -week visit will be imputed 
based on observed changes in HbA1c fro m baseline val ues at the visit fro m patients in the same 
treatm ent group who had their efficacy assessed after early discont inuat ion of study  drug and/or 
initiation of rescue antihyperglycemic medicat ion.  With the aid of the ANCOVA 2 -sided 97.5% 
CI for the difference i n mean change in HbA1c from baseline to the 52- week visit between 
LY3298176 10 m g and insulin degludec as well as between LY3298176 15 m g and insulin 
degludec will  be constructed.  Analysis will be conducted with mult iple imputations, and 
statist ical infer ence over m ultiple imputati ons will  be guided by the method proposed by  Rubin 
(1987).  If the upper limit of the CI is below 0.3%, the LY3298176 dose will be declared 
non-inferior to insulin degludec .
For all other purposes, the primary efficacy  analysis w ill be guided by the “efficacy” est imand 
defined in Sect ion 10.3.1 .  This assessment will be conducted using EAS.  The primary analysis 
model for HbA1c m easurements over time will be an MMRM.  The response variable o f 
MMRM will be change in HbA1c fro m baseline values obtained at each scheduled postbaseline 
visit.  The independent variables of the MMRM model are treatment, visit, and treatment -by-visit 
interact ion, country , baseline conco mitant oral  antidiabet ic treatment (metformin alo ne, 
metformin plus an SGLT -2 inhibitor) as fixed effe cts, and baseline HbA1c as a covariate .  
Two-sided 97.5% C Iswill be constructed for the difference in mean change in HbA1c fro m 
baseline to the 52 -week visit between LY3298176 10 m g and insulin deg ludec,as well as 
between LY3298176 15 m g and insulin degludec.  If the upper limit of the CI is below 0.3%, the 
LY3298176 dose will be declared noninferior to insulin deglu dec.
Since they  are intended for different purposes, each of the 2 primary  efficacy assessments will be 
conducted at a family -wise ty pe 1 error rate of 0.05.  Addit ional details, including analysis 
methods for key  secondary endpoints and a strategy  for con trolling the overall family -wise ty pe 
1 error rate at an alpha of 0.05 for primary and key secondary  endpoint eval uation will  be 
provi ded in the SAP.
10.3.3.2. Secondary Analyses
The secondary  study  objectives subject to ty pe 1 error rate control are as follows:
noninferi orityof the 5 m g LY3298176 dose to insulin degludec relat ive to mean change 
in HbA1c from baseline to the 52
-week visit
superi ority of each LY3298176 dose to insulin degludec relative to mean change in 
HbA1c fro m baseline to the 52 -week visit
superi orityof each LY3298176 dose to insulin degludec relative to m ean change in body  
weight from baseline to the 52 -week visit
superi ority of each LY3298176 dose to insulin degludec relative to proportion of patients 
achieving the target value of HbA1c < 7% at the 52 -week visit
The ty pe I error -controlled strategy  for the primary and secondary  endpoints will be described in 
the SAP.  All t ype I error -controlled secondary efficacy analyses will be conducted relative to 
both estimands, the “efficacy” est iman d and the “treatm ent-regimen” est imand.
I8F-MC-GPG H(c) Clinical Protocol Page 70
LY3298176Analysis of change fro m baseline in body  weight at the 52 -week visit will be conducted in a 
manner similar to the primary efficacy analyses with change in weight fro m baseline as the 
response variable and baseline bo dy weight as a covariate.
Com parisons am ong treatm ents relative to the proportion of patients achieving the HbA1c target 
value of <7.0% (53 mmo l/mol) at the 52 -week visit will be conducted using a logist ic regressio n 
analysis with terms of treatment, coun try, SGLT -2i use (Yes or No), and baseline HbA1c as a 
covari ate.  In the analysis o f patients achieving the HbA1c target value relat ive to the “efficacy” 
estimand, subjects with missing values at the 52- week visit will be excluded.  In the analysis of 
patients achieving the HbA1c target value relat ive to the “treat ment-regimen” estimand, missing 
values at the 52 -week visit will be imputed based on observed data at respective visits fro m 
patients in the same treatment group who had their efficacy assessed aft er early  discontinuat ion 
of study  drug and/or init iation of rescue medicat ion.  The analysis will be conducted with 
multiple imputations and statist ical inference over mult iple imputations will be guided by the 
method proposed by  Rubin (1987).
10.3.3.3. Tertiary/Exp loratory Analyses
All exploratory  efficacy analyses will be guided by the “efficacy” estimand and will be 
conducted using the EAS.  Details will be provided in the SAP.
10.3.4. Safety Analyses
Unless specified otherwise, safet y assessments will be guided by  an est imand co mpar ing safety  
of LY3298176 doses wi th insulin degludec irrespective of adherence to study  drug or init iation 
of rescue therapy .  Thus, safet y analyses will be conducted using the SAS.  Selected safet y 
analyses will be conducted after excluding dat a on rescue therapy .
Adverse events will be coded from the actual term using the Medical Dict ionary for Regul atory  
Activities (MedDRA) and reported with preferred terms and system organ class.  Selected 
notabl e AEs of interest may be reported using high -level terms or Standardized MedDRA 
Queri es.  Summary  statistics will be provided for incidence of TEAEs, SAEs, study  
discontinuat ion due to AEs, study  drug di scont inuation due to AEs, deaths, and other CV 
endpo ints.  Counts and proportions of subjects experi encing AEs will be reported for each 
treatm ent group, and Fisher’s exact test will be used to compare the treatment groups.
10.3.4.1. Hypoglycemic Events
Incidence of documented symptomat ic hypoglycemia events and severe hypoglycemia in each 
category  (either total  or nocturnal ) will  be com pared between LY3298176 doses and insulin 
degludec using negat ive binomial regressio n analysis. Selected safety analyse s may  be 
conducted excluding data after theintroduc tion of another anti -hyperglycemic therapy  (for 
example, rescue therapy ).
10.3.4.2. Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting, and diarrhea will be 
provi ded by each treatm ent.
I8F-MC-GPG H(c) Clinical Protocol Page 71
LY329817610.3.4.3. Adjudicated Cardiovascular Events
Listings of deaths, myo cardi al infarct ions, strokes, and hospitalizat ion for unstable angina 
confirmed by an independent CEC will be provided.  The dates of rando mizat ion, event, first 
dose and l ast dose of study  drug, and time from  rando mizat ion to the event will be listed.
10.3.4.4. Central Laboratory Measures, Vital Signs, and Electrocardiograms
Values and change from baseline to postbaseline values of central laboratory  measures, vital 
signs, and selected ECG para meters will be summarized at each scheduled visit.  The analysis 
model to m ake co mpar isons amo ng treatment groups relative to continuous change fro m baseline 
values assessed over time will be an MMRM similar to the primary  efficacy  analysis and wit h 
baseli ne m easurement as a covariate.  An unstructured covariance structure will model 
relationship of wit hin-patient errors.
The percentages of pat ients withTEabnormal, high, or low laboratory measures at any time will 
be summarized and compared between treatm ent groups by  using Fisher’s exact test.  A TE
abnorm al value i s defined as a cha nge from  normal  value at bas elineto a val ue greater than the 
high limit at any  time during Periods I I and III.  A TElow result is defined as a change fro m a 
value greater th an or equal to the low limit at baseline to a value less than the low limit at any  
time during Periods II and III.   The high and low limits will be provided in the SAP.
10.3.5. Evaluation of Immunogenicity 
The frequency and percentage of patients with preexist ingADA ,with TE ADA , and wi th 
neutralizing TEADA to LY3298176 willbe tabul ated by LY3298176 dose. 
Treatment -emergent ADAs are defined as those with a titer 2- fold (1 dilution) greater than the 
minimum required dilut ion if no ADAs were detected at baseline (treatm ent-induced ADA) or 
those wi th a 4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA).  For the TE ADA pat ients the distribut ion of maximum titers 
will be described.  The frequency of neutralizing ant ibodies to LY3298176 and/or cross -reactive 
and neutralizing ant ibodies to endogenous couterparts willbetabulated in TE ADA patients .
The relat ionship between the presence of ant ibodies and LY3298176 PK and PDresponse
including safet y and efficacy to LY3298176 maybe assessed.
10.3.6. Other Analyses
10.3.6.1. Health Economics
Analyses of actual and change fro m baseline in patient -reported outcome (PRO) scores will be 
conducted using linear models wit h baseline PRO scores, treatment and other factors that m ay be 
considered relevant.  These variables will be specified in the SAP.
10.3.6.2. Subgroup Analyses
Subgroup analyses of mean change in HbA1c from baseline to Visit 18 will be provided by age, 
race, ethnicit y, gender, duration of diabetes, baseline HbA1c ( ≤8.5%, > 8.5%), and baseline 
SGLT -2i.
I8F-MC-GPG H(c) Clinical Protocol Page 72
LY329817610.3.7. Interim Analyses
No interim analyses of efficacy are planned for this study .  If an unplanned interim analysis is 
deem ed necessary , the appropri ate Lilly medical director, or designee, will be consulted to 
determine whether it is necessary  to am end the protocol .
A data monitoring committee (DMC) will have the responsibilit y to revi ew unblinded interim 
analyses results in order to monitor the safet y of the pati ents in the study .  A sponsor stati stical 
analysis group external to t he study team will perform the data analysis for the DMC.  As no 
efficacy  analyses are pl anned by  the DMC, the family -wise error rate will not be affected by  any 
one of these interim analyses; hence no alpha spending is necessary .
Study  sites will receive informat ion about interim results ONLY if deemed necessary for the 
safet y of their pati ents.
I8F-MC-GPG H(c) Clinical Protocol Page 73
LY329817611.References
Albert i KG,Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabet Med. 1998;15(7):539 -553.
American Diabetes Associat ion. Glycemic Targets. Sec 6. In Standards of Medical Care in 
Diabetes —2017. Diabetes Care . 2017;40( suppl 1):S48 -S56. Available at:
http://care.diabetesjournals.org/content/40/Su pplement_1/S48. Accessed August 6 , 2018.
Aroda AR, Bailey TS, Cariou B, Kumar S, Lei ter LA, Raskin P, Zacho J, Andersen TH, 
Philis -
Tsmikas A. Effect of adding insulin degludec to treatment in pat ients with type 2 
diabetes inadequately  controlled wi th metformin and liraglut ide: a double -blind rando mized 
controlled trial (BEGIN: add t o GLP -1 study ). Diabetes Obes Metab. 2016;18(7):663 -670.
Asmar M, Simo nsen L, Asmar A, Holst JJ, Dela F, Bulow J. Insulin plays a permissive role for 
the vasoactive effect of GIP regulating adipose tissue metabo lism in humans. J Clin 
Endocrinol Metab 2016;101:3155-3162.
Banks PA, Freeman ML. Practice guidelines in acute pancreatit is. Am J Gastroenterol .
2006;101(10):2379 -2400.
Bradl ey C. The di abetes treatm ent satisfact ion questionnaire: DTSQ. In: Bradley C, editor.
Handbook of Psy chology and Diabetes: a guide to psycho logical measurement in diabetes 
research and practice. Chur, Switzerland: Harwood Academic Publishers; 1994.
Coskun T, Sl oop KW, Loghin C, Alsina -Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, 
Cabrera O, Roell WC, Kuchibhot la U, Moyer s JS, Benson CT, Giemeno RE, D’Alessio DA, 
Haupt A. LY3298176, a novel dual GIP and GLP -1 receptor agonist for the treatment of ty pe 2
diabetes nellitus: From discovery to clinical proof of concept. Molecular Metab . 2018
Available at :  https://doi .org/10.1 016/j.mo lmet.2018.09.009 .  Published October 2018.
Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P. A randomized trial 
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in 125 
preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the
PRESCHOOL study ). Pediatr Diabetes . 2013;14(8):593 -601. 
EuroQoL Group. EQ -5D- 5L User guide : basic info rmation on how to use the EQ - 5D-5L 
instrum ent. Versi on 2.1. Available at: 
https://euroq ol.org/wp -content/upl oads/2016/09/EQ -5D- 5L_UserGuide_2015.pdf. Published
April 2015 . Accessed August 6 , 2018.
Frias JP, Nauck MA, Van J, et al. Efficacy and safety  of LY3298176, a novel dual GIP and GLP -
1 receptor agonist, in patients with ty pe 2 di abetes: a randomised, placebo -controlled and 
active co mparator -controlled phase 2 trial. [published online October 4, 2018]. Lancet.
https://doi .org/10.1016/S0140 -6736(18)32260-8.
Hayes RP, DeLozier AM. Reliabilit y, validit y, and responsiveness o f the Impact of  Weight on 
Self-Percept ions Questionnaire (IW -SP) in individuals with ty pe 2 diabetes and obesit y. 
Diabetes Technol Ther . 2015;17(3):210 -214.
I8F-MC-GPG H(c) Clinical Protocol Page 74
LY3298176Hayes RP, Nel son DR, Meldahl ML, Curtis BH. Abilit y to perform  daily  physical  activi ties in 
individuals wit h type 2 diabetes and m oderate obesit y: a preliminary validation o f the Impact 
of Wei ght on Activit ies of Daily Living Quest ionnaire. Diabetes Technol Ther . 
2011;13(7):705 -712.
Hayes RP, Schul tz EM, Naegeli  AN, Curti s BH. Test -retest, responsiveness, and minimal 
important change o f the abilit y to perform physical activit ies of daily living quest ionnaire in 
individuals wit h type 2 di abetes and obesit y. Diabetes Technol Ther . 2012;14(12):1118- 1125.
Inzucchi SE, Bergenstal RM, Buse JB, Di amant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of hyperglycemia in t ype 2 diabetes, 2015: a 
patient-centered approach: update to a posit ion statem ent of  the Ameri can Diabetes 
Associ ation and the European Assoc iation for the Study  of Diabetes. Diabetes Care.
2015;38(1):140 -149.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management 
of acute pan creati tis: diagnosti c criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg .
2006;13(1):25 -32.
Nauck M. Incretin therapies: highlight ing commo n features and differences in the modes of 
action of  glucagon -like peptide -1 agonists and dipeptidyl pept idase -4 inhibitors. Diabetes 
Obes Metab. 2016;18(3):203 -216.
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medicat ions and the risk o f 
acurte pancreatitis an/or pancreatic cancer: Reassuring data from cardio -vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9): 1327 -1328. 
Nauck MA, Meier JJ. Incret in hormones: The ir role in healt h and disease. Diabetes Obes Metab .
2018:20(Suppl.1) :5-21.
PanC, Gross JL,Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R. A mult inational, 
rando mized, open -label, treat
-to-target trail co mparing insulin degludec and insulin glargine in 
insulin -naïve patients with ty pe 2 di abetes m ellitus. Drugs RD .2016;16:239 -249.
Philis -Tsimikas A, Brod M, Niemeyer M, Francisco AMO, Rothman J. Insulin degludec 
once -daily  intype 2 di abetes: simple or step -wise titration (BEGIN: once simple use). Adv 
Ther. 2013; 30:607-622.
Ratner, RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B .
Hypoglycaemia risk with insulin degludec compared with insulin glargine in t ype 2 and ty pe 1 
diabetes:a pre -planned meta -analysis o f phase 3 trials . Diabetes, Obesity and Metabol. 
2013;15 (2):175-184.
Rubin DB. Mult iple imputati on for nonresponse in surveys. New York: John Wiley & Sons Inc.; 
1987.
Steinberg WM, Buse J B, Ghorbani MLM, Ørsted DD
, Nauck MA; LEADER Steering 
Committee; LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in peopl e 
with type 2 diabetes treated with liraglut ide: results 
from the LEADER Rando mized Trial.
Diabetes Care .2017a;40( 7):966 -972.
I 8 F -M C -G P G H( c) Cli ni c al Pr ot o c ol P a g e 7 5 
L Y 3 2 9 8 1 7 6 Stei n ber g W M, R ose nst oc k J, Wa d de n T A, D o ns mar k M, Je nse n C B, De Vries J H. I m pact of 
lir a gl ut i de o n a m ylase, li pase, a n d ac ute pa ncreat it is i n part ic i pa nts wi t h  o ver wei g ht/ o besi t y  
a n d n or m o gl yce mia, pre dia betes, or t y pe 2 di a betes: sec o n dar y  a nal yses of p o o le d data fr o m 
t h e S C A L E cli nical de vel o p me nt pr o gra m. Di a betes C are .2 0 1 7 b ; 4 0( 7): 8 3 9 - 8 4 8. 
Tresi ba [ U S pac ka ge i nsert ( U S PI)]. I n dia na p o lis, I N: Eli Lill y a n d C o m pa n y; 2 0 1 5. A vaila ble 
at: htt ps:// w w w.access data.f da. g o v/ dr u gsat f da _ d ocs/la bel/ 2 0 1 5/ 2 0 3 3 1 4l bl. p df .
Vora J, C o he n N, E va ns M, H oc ke y  A, S pei g ht J, W hatel y -S mi t h  C . I nte nsif yi n g i ns uli n re gi me n 
af ter basal  i ns uli n o pti mizat i o n i n a d ults wit h t y pe 2 dia betes: a 2 4 -wee k, ra n d o mize d, o pe n -
la bel trial c o m par i n g i ns uli n glar gi ne pl us i ns uli n gl ulisi ne wit hbi p hasic i ns uli n as part 
( La n Sca pe) . Di a betes, O besity a n d Met a b . 2 0 1 5; 1 7( 1 2): 1 1 3 3 - 1 1 4 1 .
Wei n ber g M E, Bacc hetti P, R us ha k off RJ. Fre q ue nt l y re peate d gl uc ose m eas ure me nts 
o veresti mate t he i nci de nce of i n patie nt h y p o gl yce mia a n d se vere h y per gl yce mia. J Di a be tes 
Sci Tec h n ol . 2 0 1 0; 4( 3): 5 7 7 - 5 8 2. 
Zi n ma n B, P hilis -Tsi mi kas A, Cari o u B, Ha n dels ma n Y, R o d bar d H W, J o ha nse n T, E da hl L, 
Mat hie u C o n be half of t he N N 1 2 5 0 -3 5 7 9 ( B E GI N O nce L o n g) Trial I n vest i gat ors. I ns uli n 
de gl u dec vers us i ns uli n glar gi ne i n i ns uli n -naï ve pati e nts wi t h  t y pe 2 dia betes. A 1 -year, 
ra n d o mize d, treat -t o -tar get tri al  ( B E GI N O nce L o n g). Di a betes C are .2 0 1 2; 3 5: 2 4 6 4 -2 4 7 1. 
I8F-MC-GPG H(c) Clinical Protocol Page 76
LY329817612.Appendices
I8F-MC-GPG H(c) Clinical Protocol Page 77
LY3298176Appendix 1. Abbreviations and Definitions
Term Definition
ADA anti-drug antibodies
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (includ ing an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALT alanine aminotransferase
ANCOVA analy sis of covariance
APPADL Ability to Perform Physical Activities of Daily Living
AST aspartate aminotransferase
BG blood glucose
BP blood pressure
CEC clinical endpoint committee
CHF congestive heart failure
CI confidence interval
CKD- EPI Chro nic Kidney Disease -Epidemiology
CIOMS Council forInternational Organizations ofMedical Sciences
Com panion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therap eutic product
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
COVID -19 Coronavirus Disease 2019
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
I8F-MC-GPG H(c) Clinical Protocol Page 78
LY3298176CSR clinical study report
CT computed tomography
CV cardiovascular
CVD cardiovascular disease
DMC data monitoring committee
DPP-4 dipeptidy l-peptidase -4
DTSQ c Diabetes Treatment Satisfaction Questionnaire change
DTSQ s Diabetes Treatment Satisfaction Questionnaire status
EAS efficacy analysis set
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the study are 
those who have been assigned to a treatment.
enter Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
EQ-5D-5L European Quality of Life
ERB ethical review board
ET early  termination
FAS full analy sis set
FBG fasting blood glucose
FSH follicle -stimulating hormone
GAD glutamic acid decarboxylase
GCP good clinical practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GLP-1 glucagon -like peptide -1
HbA1c hemoglobin A1c
I8F-MC-GPG H(c) Clinical Protocol Page 79
LY3298176HDL high-density lipoprotein
HR heart rate
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
Informed consent A process by which a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
means of a written, sig ned and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
INR internatio nal no rmalized ratio
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed , and analy zed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive voice -response sy stem/interactive web -response system
IW-SP Impact of Weight on Self -Perception
MedDRA Medical Dictionary for R egulatory  Activities
mITT modified intention -to-treat
MMRM mixed- model for repeated measures
MTC medullary thyroid carcinoma
NAFLD nonalcoholic fatty liver disease
OAM oral antihy pergly cemic medications 
OTC over the counter
PG plasma glucose
PK/PD pharmacokinetics/pharmacodynamics
I8F-MC-GPG H(c) Clinical Protocol Page 80
LY3298176PP per-protocol
PPS per-protocol set:  The set of data generated by the subset of patients who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, accor ding to the underlying scientific model.
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
QTc corrected QT interval
QD once daily
QW once weekly
SAD single ascending dose
SAE serious adverse event
SAP statistical analysis plan
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2
SAS safety  analy sis set
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SD standard deviation
SDP single dose pen
SGLT -2i sodium -glucose co -transporter -2 inhibitor
SMBG Self-monitored blood glucose
SUSARs suspected unexpected serious adverse reactions
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TG triglycerides
TTT treat-to-target
I8F-MC-GPG H(c) Clinical Protocol Page 81
LY3298176Tx treatment
ULN upper limit of normal
VLDL very low density  lipoprotein
I8F-MC-GPG H(c) Clinical Protocol Page 82
LY3298176Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Testsa
Hematology Clinical Chemistry
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RB C)
Mean cell volume
Mean cell hemoglobin concentration
Leukocytes (WBC)
Neutrophils, segmented
Lymphocy tes
Monocytes
Eosinophils
Basophils
PlateletsPotassium
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine
Uric acid
Calcium
Glucose, fasting
Urinaly sis
Albumin
CreatininePregnancy Test (females only) b
Follicle -stimulating hormone (FSH)c
Estradiolc
HbA1c
eGFR (calculated by CKD -EPI equation)d
Endocrine
Calcitonin
Anti-GAD AntibodiesPancreas (exocrine)
Serum pancreatic amylase
Serum lipase
Immunogenicity
LY3298176 anti -drug antibody
Nonpharmacogenetic Stored Samples:
EDTA plasma
Serum
P800 plasma
Pharmacogenetic Stored SampleLipid Panel (fasting)
Total cholesterol
LDL
HDL
VLDL
Triglycerides
I8F-MC-GPG H(c) Clinical Protocol Page 83
LY3298176Abbreviations: CKD -EPI =Chronic Kidney Disease -Epidemiology; EDTA =ethylenediaminetetraacetic acid ; 
eGFR =estimated glomerular filtration rate; GAD = glutamic acid decarboxylase ;HbA1c =hemoglobin A1c; 
HDL =high-density lipoprotein cholesterol; LDL =low-density lipoprotein cholesterol; PK =pharmacokinetics; 
RBC =red blood cells ; VLDL =very low -density  lipoprotein cholesterol ; WBC =white blood cells .
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted .
bSerum pregnancy test will be performed by central laboratory at Visit 1 for women of childbearing potential; A 
urine pregnancy testmust be perfo rmed at Visit 3 with the result available prior to randomization and first 
injection of study drug(s) for women of childbearing potential only . Additional pregnancy tests will be 
performed at Visits 13, 17, 19 and 21. Pregnancy tests may alsobe performed at the investigator’s discretion 
during the study.  If required per local regulations and/or institutional guidelines, pregnancy testing can also 
occur at other times during the study treatment period
cFollicle -stimulating hormone test perfo rmed at Visit 1 for postmenopausal women at least 45years of age with an 
intact uterus, not on hormone therapy, and who have had spontaneous amenorrhea for more than 6 months and 
less than 12 months and estradiol levels consistent with a postmenopausal sta te (FSH ≥40 mIU/mL and estradiol 
<30 pg/mL).
dEstimated glomerular filtration rate will be calculated by the central laboratory at all visits and included in 
laboratoryresult repo rts.
I8F-MC-GPG H(c) Clinical Protocol Page 84
LY3298176Appendix 3. Study  Governance Considerations
Appendix 3.1.Regulatory and Ethical C onsiderations, Including the 
Informed Consent Process
Appendix 3.1.1 .Informed Consent
The invest igator is responsible for:
ensuring that the patie ntunderstands the nature of the study , the potential 
risks and benefits of participat ing in the study , and that thei r parti cipat ion is 
voluntary.
ensuring that informed consent is given by each patientor legal 
representative.  This includes obtaining the appropriate signatures and dates 
on the informed consent form ( ICF) prior to the performance o f any protoco l 
procedures and prior to the administration of investigat ional product.
answering any quest ions the patientmay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his o r her participation in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the 
participant’s l egal representative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the 
date the written consent was obtained. The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
Appendix 3.1.2 .Recruitment
Lilly or its designee is responsible for the central recruit ment strategy  for pati ents.  Individual 
investigators may have addit ional local requirements or processes.
Appendix 3.1. 3. Ethical Review
The invest igator or an a ppropri ate local representative must give assurance tha t the ethi cal 
review board (ERB) was properly  consti tuted and convened as required by Internat ional Council
for Harm onisat ion (ICH) guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be prov ided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guid eline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
I8F-MC-GPG H(c) Clinical Protocol Page 85
LY3298176theprotocol and related amendments and addenda ,current Invest igator ’s
Brochure ( IB) and updates during the course of the study
ICF
other relevant docum ents ( for example , curri cula vi tae, adverti sements)
Appendix 3.1. 4. Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with the:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP Guidelines
applicabl e laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
Appendix 3.1 .5. Investigator Information
Physicians with a specialt y indiabetes/endocrinology , internal  medicine, family  medicine, 
general medicine , or any  other speci alty physician who has experience treating t ype 2 diabetes
with clinical  research experience will parti cipate as invest igators in this clinical study .
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will appr ove the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
The clinical study  report ( CSR )coordinating investigator will sign the final CSR for this study , 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
A qualified invest igator will serve as the CSR coordinat ing invest igator.  If this invest igator is 
unable to fulfill this funct ion, another invest igator will be chosen by Lilly to serve as t he CSR 
coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the stu dy.
Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
I8F-MC-GPG H(c) Clinical Protocol Page 86
LY3298176provi de instructi onal materi al to the study  sites, as appropriate
provi de sponsor start- up training to instruct the investigators and study  
coordinators.  This training will give instruction on the protocol, the complet ion 
of the eCRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and verify  data reported to detect potential errors 
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The st udy may be audited by  Lilly or i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator is respons ible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the sponsor. 
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data. The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Addit ionally , clinical  outcom e assessment data (scales, self -reported di ary data) will  be collected 
by the subject/invest igator site personnel, via a paper source document and will be transcribed by 
the invest igator site personnel into the EDC sy stem.
Data collected via the sponsor- provided data capture systems will be stored at third parties .  The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommiss ioning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and electronic transfers will be provi ded to the invest igator 
for review and retent ion.Data will subsequently be transferred fro m the central  vendor to the 
Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anage ment sy stem .
I8F-MC-GPG H(c) Clinical Protocol Page 87
LY3298176Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator , or the ERB 
of the study  sitejudges it necessary for medical , safet y,regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent wi th applicable laws, regulat ions, and GCP.
Appendix 3. 4. Publication Policy
The publicat ion policy for Study  I8F-MC-GPGH is described in the Clinical Trial Agreement .
I8F-MC-GPG H(c) Clinical Protocol Page 88
LY3298176Appendix 4. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests may be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT =alanine aminotransferase; AST =aspirate aminotransferase; CPK =creatinine 
phosphokinase; GGT =gamma -glutamyl transferase; Ig =immunoglobulin; INR =internatio nal normali zed
ratio; RBC =red blood cells; WBC =white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I8F-MC-GPG H(c) Clinical Protocol Page 89
LY3298176Appendix 5. World Health Organization Classification 
of Diabetes and Diagnostic Criteria
Type 1 Diabetes:   Type 1 di abetes is j udged to be present when the classical symptoms of 
diabetes (thi rst, polyuri a, wast ing and stupor, or coma) are associated with readily  detectabl e 
concentrations of glucose and ketone bodies in the blood and urine.  Insulin treatment is 
necessary  not only to control  hyperglycemia but also to prevent spontaneous ketosis and death.
Type 2 Diabetes:   Type 2 di abetes, al though often a symptom atic, may also present with 
classical hyperglycemic symptoms (thirst, polyuria, weight loss), but despite hy perglycemia, 
ketone bodi es are present in only low concentrations in the blood and urine.  Coma is rare in ty pe 
2 diabetes ,but m ay resul t from extrem e hyperglycemia and hyperosmo larity; lactic aci dosis or 
ketoacidosis can also occur in fulminat ing illness (for example, severe infect ion or m esenteri c 
artery  throm bosis) due to an acute increase in insulin requirements, but spontaneous ketosis do es 
not occur.  Some patients with t ype 2 diabetes later progress to a state of abso lute insulin 
deficiency (Albert i and Zimmet 1998). 
I8F-MC-GPG H(c) Clinical Protocol Page 90
LY3298176Appendix 6. Classification of Contraceptive Methods
Highly Effective Methods of Contraception:
Combined oral contraceptive pill and mini pill
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total  abstinence (if this is their preferred and usual lifestyle) or in a same- sex rel ationship 
with no sexual  relati onship wi th males (as part of their preferred and usual lifest yle).  
Note:  periodic abst inence ( for example , calendar, ovul ation, symptothermal, 
postovulat ion methods), declarat ion of abs tinence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception
Vasectomy  –for men in clinical studies
Effective Methods of Contraception (must use combination of 2 methods):
Male condom wit h spermicide
Female condo m with spermicide
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
Men, regardless of their fertilit y status, with non -pregnant wom en of child bearing potential 
partners must agree to either remain abstinent (if this is their preferred and usual lifest yle) or use 
condoms plus one addit ional highly  effect ive (less than 1% failure rate) method of contraception 
(such as co mbinat ion oral  contraceptives, implanted contraceptives or intrauterine device) or 
effect ive method of contraception, (s uch as diaphragms with spermicide or cervical sponge) for 
the duration of the study  and for at l east 3 m onths after the l ast injection
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated rel evant potenti al exposure in wom en of childbearing potential. 
Men who are in exclusively same sex relat ionships (as their preferred and usual lifest yle) are not 
requi red to use contraception. 
I8F-MC-GPG H(c) Clinical Protocol Page 91
LY3298176Appendix 7. Changes to Study  Procedures due to the 
COVID -19 Pandem ic
Severe acute respiratory  syndrome coronavirus 2 ( SARS -CoV -2), the virus that causes the novel
COVID -19 pandemic ,has caused numerous gl obal restrict ions to be enacted that may impact a 
patient’s abilit y and/or willingness to attend their onsite study visit as original lyscheduled .  
In 
such a situation, please fo llow the gui dance below :  
1)Patients shoul d com e for the primary  endpoint visit (Visit 21) at the ori ginally planned 
52-week (± 7 days) schedule whenever possible and safe to do so, at the invest igator's 
discreti on.  
However, in order to maximize the abilit y for onsi te visi ts for Vi sit 21, 
minimize missing data ,and preserve the intended conduct of the study, the visit window 
for Visit 21 m ay be brought forward no sooner than 14 days (Week 5 0) or extended up to 
8weeks (Week 60).  The subsequent safety follow-up visit  (Visi t 801) shoul d take pl ace 
4weeks ±7 day s after Vi sit 21.  
2)For patients requiring an extensio n for Visit 21 up to Week 60, addit ional IP will be 
provi ded to allow patients to rem ain on study  drug uninterrupted during the extended 
treatm ent peri od, to ensure patient safet y
,and to maintain the overall integrityof the tri al. 
3)Addit ional consent from the pati entwill be obtained per local regulat ions for those 
patients who wil l be dispensed addit ional IP during the extended treatment period.
4)The sites will need to ident ify and document the details of how all patients and visits 
were affected by the COVID -19 pandemic restrict ions.
5)Mobile (in -home) healthcare visits: 
Mobile visits may be performed at patients’ homes when patients cannot travel to the 
site due to extenuating circumstances. These will be performed by a qualified ho me 
nursing service provider fo llowing sponsor approval, if permitted by  local 
regul ations.Procedures performed may include, but are not limited to, taking blood 
samples, conducting physical assessments, administering PROs, and co llecting healt h 
inform ation. Please note that requirements related to the reporting of SAEs remain 
unchanged. Every effort shoul d be made for the patientto return to onsite visit s as 
soon as reasonably  possible, while ensuring the safety  of the patientand 
investigat ional site staff. 
Addit ional consent fro m the patientwill be obtained for those who participate in 
home healt h services.
I8F-MC-GPGH(c) Clinical Protocol Page 92
LY3298176Appendix 8. Protocol A mendment I8F-MC-GPGH (c)
A Randomized, Phase 3, Open -Label Trial Comparing 
the Effect of LY3298176 versu s Titrated Insulin Degludec 
on Gly cemic Control in Patients with Ty pe 2 Diabetes 
(SURPA SS-3)
Overview
Protocol  I8F-MC-GPGH ti tled “A Randomized, Phase 3, Open -Label Tri al Com paring the Effect 
of LY3298176 versus Titrated Insulin Degludec on Glycemic Control  in Pat ients with Type 2 
Diabetes (SURPASS -3)” has been amended.  The new protocol is indicated by  amendment ( c) 
and will be used to conduct the study  in place of any  preceding versio n of the protocol.
The overall changes and rationale for the chang es made to thi s protocol  are described in the 
following table.  
I8F-MC-GPGH(c) Clinical Protocol Page 93
LY3298176Amendment Summary for Protocol I8F -MC-GPGH Amendment ( c)
Section # and Name Description of Change Brief Rationale
Appendix 7 Added language about the mobile 
(in-home) healthcare visits.This provides an option to conduct a clinical 
trial visit and all the applicable procedures in a 
mobile healthcare facility or at the home of a 
patient when the patient is not able or not 
willing to go to the site due to COVID -19 
restrictions.
L e o  D o c u m e n t  I D  =  c 9 2 6 3 6 0 1 - f a a e - 4 f c 1 - a 1 d 0 - 1 e 1 9 d 7 b 2 e d b f 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  3 0 - J u l - 2 0 2 0  1 5 : 2 5 : 0 1  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  3 0 - J u l - 2 0 2 0  2 0 : 2 8 : 0 9  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 